Molecular characterization of human, bovine, and dolphin parainfluenza viruses: viral genome sequencing and epithelial cell signaling responses following in vitro infection by Eberle, Kirsten Charlotte
Graduate Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2015
Molecular characterization of human, bovine, and
dolphin parainfluenza viruses: viral genome
sequencing and epithelial cell signaling responses
following in vitro infection
Kirsten Charlotte Eberle
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/etd
Part of the Allergy and Immunology Commons, Cell Biology Commons, Immunology and
Infectious Disease Commons, Medical Immunology Commons, and the Molecular Biology
Commons
This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University
Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University
Digital Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Eberle, Kirsten Charlotte, "Molecular characterization of human, bovine, and dolphin parainfluenza viruses: viral genome sequencing
and epithelial cell signaling responses following in vitro infection" (2015). Graduate Theses and Dissertations. 14829.
https://lib.dr.iastate.edu/etd/14829
!!
 
Molecular characterization of human, bovine, and dolphin parainfluenza 
viruses: Viral genome sequencing and epithelial cell signaling responses 
following in vitro infection 
 
by 
 
Kirsten Charlotte Eberle 
 
A dissertation submitted to the graduate faculty 
in partial fulfillment of the requirements for the degree of 
DOCTOR OF PHILOSOPHY 
 
Co-Majors: Molecular, Cellular, & Developmental Biology and Immunobiology 
 
Program of Study Committee: 
Randy E. Sacco, Co-Major Professor 
Cathy L. Miller, Co-Major Professor 
Mark R. Ackermann 
Amy H. Andreotti 
Christine A. Petersen 
 
 
Iowa State University 
Ames, Iowa 
2015 
 
 
Copyright © Kirsten Charlotte Eberle, 2015. All rights reserved. 
!!
ii 
DEDICATION 
 
 
To my hero: Plain Grandma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!!
iii 
TABLE OF CONTENTS !!
 Page 
 
DEDICATION.......................................................................................................  ii 
 
CHAPTER 1: GENERAL INTRODUCTION AND LITERATURE REVIEW..........  1 
 Dissertation Organization..........................................................................  1 
 Literature Review......................................................................................  1 
 Paramyxoviruses............................................................................  1!
 Use of epithelial cells for in vitro experiments................................  7!
 Cytokines produced in response to viral infection........................  10!
 Phosphoproteomics.....................................................................  18!
 Hypothesis and Aims..............................................................................  21!
 References..............................................................................................  22!!
CHAPTER 2: NOVEL ATLANTIC BOTTLENOSE DOLPHIN  
PARAINFLUENZA VIRUS TtPIV-1 CLUSTERS WITH BOVINE PIV-3 
GENOTYPE B STRAINS...................................................................................  36 
 Abstract...................................................................................................  37!
 Introduction.............................................................................................  38!
 Materials and Methods............................................................................  40!
 Results....................................................................................................  44!
 Discussion...............................................................................................  56!
 Acknowledgements.................................................................................  61!
 References..............................................................................................  61!!
CHAPTER 3: PIV-3 BLOCKS ANTIVIRAL MEDIATORS DOWNSTREAM  
OF THE IFN-λR BY MODULATING STAT1 PHOSPHORYLATION.................  65!
 Abstract...................................................................................................  65!
Importance..............................................................................................  66!
Introduction.............................................................................................  67!
Materials and Methods............................................................................  70!
Results....................................................................................................  75!
Discussion...............................................................................................  89!
Funding Information................................................................................  92!
References..............................................................................................  92!!
CHAPTER 4: PHOSPHOPROTEOMIC ANALYSIS OF HOST  
EPITHELIAL CELL SIGNALING RESPONSES DURING INFECTION  
WITH PARAINFLUENZA VIRUS 3 IN VITRO.................................................... 97 
Abstract...................................................................................................  97!
Introduction.............................................................................................  98!
Materials and Methods..........................................................................  100!
Results .................................................................................................. 104!
!!
iv 
Discussion.............................................................................................  118!
Conclusions..........................................................................................  122!
Acknowledgements...............................................................................  123!
References............................................................................................  123!!
CHAPTER 5: GENERAL CONCLUSIONS AND FUTURE DIRECTION.........  128 
References............................................................................................  131 
 
APPENDIX: DEVELOPMENT AND APPLICATION OF SPECIFIC  
CYTOKINE ASSAYS IN TISSUE SAMPLES FROM A BOTTLENOSE  
DOLPHIN WITH HYPERINSULINEMIA..........................................................  134 
Abstract.................................................................................................  134!
Introduction...........................................................................................  136!
Materials and Methods..........................................................................  138!
Results..................................................................................................  141!
Discussion.............................................................................................  146!
Acknowledgements...............................................................................  150!
References............................................................................................  150!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! 1 
CHAPTER 1: GENERAL INTRODUCTION AND LITERATURE REVIEW 
 
Dissertation Organization 
 
This dissertation follows the organizational format in which each chapter is 
an independent manuscript that has been accepted, submitted or intended for 
submission.  Each chapter therefore follows the submission guidelines for a 
specific journal.  Following this paragraph begins the literature review, which 
encompasses further details pertaining to the dissertation as a whole.  Chapter 2 
has been accepted for publication in Virus Genes.  Chapter 3 has been 
submitted for publication to Journal of Virology.  Chapter 4 is formatted for 
submission to Journal of Proteome Research.  The final chapter, Chapter 5, 
includes general conclusions and future directions.  A case study published in 
Frontiers in Endocrinology can be found in the appendix.   
 
Literature Review 
 
Paramyxoviruses 
In the late 1950s, the now termed, paramxyoviruses were isolated and 
found to be distinguishable from Orthomyxoviruses or influenza viruses 
(Andrewes and Worthington, 1959; Waterson and Hurrell, 1962).  The 
Paramyxoviridae family of viruses are negative-sense single stranded RNA 
viruses which are enveloped and non-segmented (Baron and Enders, 1996; 
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Bossart et al., 2009; Chang and Dutch, 2012).  This family can be further 
subdivided into two subfamilies: Paramyxovirinae and Pneumovirinae (Aguilar 
and Lee, 2011).  The Paramyxovirinae subfamily comprises genera Respirovirus, 
Rubalavirus, Morbillivirus, Henipavirus, and Avulavirus.  Pneumovirus and 
Metapnuemovirus genera are part of the Pneumovirinae subfamily (Henrickson, 
2003; Chang and Dutch, 2012).  Human parainfluenza virus (HPIV)-1 and -3 lie 
within the genus Respirovirus, while HPIV-2 and -4 are found in the Rubulavirus 
genus.  The Paramyxoviridae family encompasses many significant viruses: 
Newcastle Disease Virus (NDV), Measles, Mumps, Nipah, Hendra, and 
Respiratory Syncytial Virus (RSV) (Henrickson, 2003; Chang and Dutch, 2012).   
Paramxyoviruses have a helical nucelocapsid that varies in size from 150-
300nm in diameter and enclose a RNA genome of 10-20kb in length (Baron and 
Enders, 1996; Battisti et al., 2012).  Figure 1 depicts the genomic and physical 
structural organization of paramyxoviruses.  The structure of a paramyxovirus 
consists of genomic RNA associated with nucleoprotein (N) and phosphoproteins 
(P) along with the large (L) protein RNA-dependent RNA polymerase (RdRp) 
within the stabilizing matrix (M) structure (Vainionpää and Hyypia, 1994).  The 
fusion (F) and hemagglutinin (H), hemagglutinin-neuraminidase (HN), or 
glycoproteins (G) protrude, like spikes, from the envelope surrounding the M 
protein (Vainionpää and Hyypia, 1994; Henrickson, 2003; Bossart et al., 2009).  
The H/HN/G and F proteins are involved in viral attachment and fusion, 
respectively, with the cell during infection (Lamb and Jardetzky 2007; Bossart et 
al., 2009).   
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Figure 1.  Genomic and structural organization of Paramyxoviridae.   
The paramyxovirus genome includes the nucleoprotein (NP) in yellow, 
phosphoprotein (P) in green, matrix (M) in orange, fusion (F) in purple, 
hemagglutinin-neuraminidase (HN) in blue, and large (L) RNA-dependent RNA 
polymerase in red. 
 
 
The viral life cycle of paramyxoviruses is similar to other RNA viruses 
(Vainionpää and Hyypia, 1994; Henrickson, 2003; Chang and Dutch, 2012).  The 
H/HN/G protein binding to the cell membrane accomplishes initial attachment of 
the virus to the host cell.  The HN protein of PIV-3 specifically attaches to N-
acetylneuraminic (sialic) acid residues and heparin sulfate moieties on the cell 
surface (Bose and Banerjee, 2002; Zhang et al., 2005).  After attachment, 
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paramyxoviruses can enter the cell through three primary means: directly at the 
plasma membrane, through an endocytic pathway, or engulfment by 
macropinocytosis.  Fusion of the F protein can be accomplished directly at the 
plasma membrane or after the virus is within an endocytic vessel in the cell.  
Upon fusion, the inactive F0 protein is proteolytically cleaved into F1 and F2 
(Bossart et al., 2009; Chang and Dutch, 2012).  In the metastable prefusion form, 
F1 and F2 are fusogenically active (Chang and Dutch, 2012).  This brief 
metastable prefusion state is followed by an irreversible conformational change 
resulting in a stable six-helix bundle and subsequent hemifusion state (Chang 
and Dutch, 2012).  After fusion the contents of the virion are dispelled into the 
cytoplasm of the cell.  Viral transcription follows where RNA-dependent RNA-
polymerase is used to produce positive-sense mRNA from negative-sense RNA 
genome template (Harrison et al., 2010).  Translation and post-translational 
modifications using cell machinery allows for production of viral proteins.  The M 
protein help organize the assembly process at the plasma membrane of a cell 
(Harrison et al., 2010).  The F and H/HN/G proteins can be seen by electron 
microscopy protruding outward from the plasma membrane of an infected cell 
(Harrison et al., 2010).  The progeny RNA genomes gather near the cell surface 
and viral budding of productive virus is accomplished. 
Human PIV’s lie within the Paramyxovirinae subfamily but are then divided 
into the Respirovirus or Rubulavirus genus depending on if they cause mainly 
lower or upper respiratory tract infections, respectively (Henrickson, 2003).  That 
is, in infants, children, elderly, or immunocompromised, HPIV-1 and -3 primarily 
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cause lower respiratory tract infections, while HPIV-2 and -4 usually cause less 
severe infections in the upper respiratory tract (Vainionpää and Hyypia, 1994).  
Simian virus 5, recently renamed PIV-5, has not been seen to cause disease in 
humans, but may be important in canine kennel cough (Chen et al., 2012).  Lung 
infections, including influenza, pneumonia, and acute lower respiratory infections, 
accounted for the highest percent of the total global burden of disease in 2002 
(Mizgerd, 2006).  Mitzgerd states that this burden is not an anomaly of a 
particular outbreak in 2002, but lung infections consistently cause more burden 
than the other diseases identified.  Specifically, PIV is the second leading cause 
of lower respiratory tract infections behind RSV, another paramyxovirus (Simoes 
et al., 2006).  PIV is a seasonal infection mainly seen in the spring and summer 
months (Boloursaz et al., 2013).  In the United States, specifically, PIV-3 
accounts for 8,700 - 52,000 hospitalizations annually (Boloursaz et al., 2013). 
Bovine PIV-3 (BPIV-3) was originally isolated in 1959 from the nasal 
discharge of a calf with shipping fever, the strain then termed myxovirus SF-4 
(Ellis, 2010).  Since 1959, many stains of BPIV-3 have been identified (list in 
Horwood et al., 2008).  Upon discovery and genome sequencing of new BPIV-3 
isolates, three genotypes have been outlined: A, B, and C.  Genotype A include 
the North American isolates (i.e. SF4, Kansas, and SK217).  The Australian 
isolates are grouped into genotype B (i.e. TVMDL15 and Q5592) and the 
genotype C isolates are those from China and Korea (i.e. 12Q061 and SD0811) 
(Horwood et al., 2008; Zhu et al., 2011; Oem et al., 2013).  Based on genomic 
sequence, these bovine strains have been found similar to the HPIV-3, but 
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unique enough that the use of a live attenuated BPIV-3 has been tried as a 
vaccine in humans (Karron et al., 1995; Karron et al., 1996).  A licensed vaccine 
for HPIV-3 is still unavailable, but work aimed at the use of chimeric viruses with 
a BPIV-3-host restricted background and HPIV-3 HN and F specificity may prove 
to be successful in the clinic (Karron et al., 2012).  BPIV-3 is commonly 
associated with bovine respiratory disease complex (BRDC), which is an 
infection with multi-factorial etiology (Kasimanickam, 2010).  For instance, a viral 
infection exacerbated by a secondary bacterial infection.   
In the recent years, the Atlantic bottlenose dolphin (Tursiops truncatus) 
population has received much publicity due to outbreaks of disease.  In August of 
2013, hundreds of bottlenose dolphins were found dead off the Atlantic Coast of 
the United States (Lallanilla, 2013; Subbaraman, 2013).  The mortality was later 
linked to an outbreak of morbillivirus, a paramyxovirus (Lee, 2013).  In 2008 
Nollens et al. reported a novel virus isolated from a bottlenose dolphin that 
exhibited signs of respiratory disease.  Clinical symptoms were similar to those 
seen in cattle or humans, included raspy breathing.  After molecular 
characterization of the virus, it was found to be similar to, but distinct from, HPIV-
3 and BPIV-3, and termed Tursiops truncatus parainfluenza virus type 1 (TtPIV-
1).  Alignment of the L and F protein sequence showed most similarity to BPIV-3 
(87% and 84%, respectively) (Nollens et al., 2008).  A dolphin specific ELISA 
measuring PIV seroconversion in bottlenose dolphins revealed that PIV is a 
common virus in this marine population (Venn-Watson et al., 2008).  Chapter 2 of 
! 7 
this dissertation reveals new details about TtPIV-1 and why this bottlenose 
dolphin PIV should be reclassified as a BPIV-3 within genotype B. 
 
Use of epithelial cells for in vitro experiments 
The human lung epithelium serves as a physical barrier against 
respiratory viruses, but also possess many other characteristics to keep 
pathogens from causing infection.  Tight junctions between epithelial cells aid in 
maintaining a barrier, or wall, to keep pathogens from reaching the basolateral 
surface (Kojima et al., 2013).  Along with antigen sampling by Microfold (M) cells, 
dendritic cell projections can protrude between the tight junctions to sense 
foreign antigen at the apical cell surface (Kim et al., 2011; Vareille et al., 2011).  
Mucociliary clearance occurs when cilia hairs “beat” to physically push microbes 
up and out of the airways.  In addition, epithelial cells are coated in a thin mucus 
layer that contains many antimicrobial peptides (AMPs) and mucins (Noah et al., 
1995; Hiemstra, 2001; Svitacheva and Davies, 2001).  Mucous cells of the 
submucosal glands and intraepithelial goblet cells at the cell surface are the main 
producers of mucus in the respiratory tract (Svitacheva and Davies, 2001).  
Homeostasis of pulmonary health is greatly controlled by AMPs of the respiratory 
tract (Meyerholz and Ackermann, 2005).  When these airway defense 
mechanisms become compromised, the epithelial cell layer becomes vulnerable 
for infection.  The primary cell type respiratory viruses infect, including 
paramyxoviruses, are airway epithelial cells.  If a pathogen is able to gain access 
into host cells, multiple antiviral substances can be produced by the airway 
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epithelium including interferons, lactoferrin, defensins, cytokines (Vareille et al., 
2011).   
 Literally meaning “in glass”, in vitro cell culture stems back to work by 
English physician Sir William Harvey in the 1500’s.  Dr. Harvey noted that a piece 
of myocardium in his hand remained contractile if covered in his own saliva 
(Harvey et al., 2001; Allen et al., 2005).  Earle developed a transformed cell line 
from subcutaneouse mouse tissue in 1943, however, it was not until 1951 that a 
human cell line was successfully isolated and cultured in a laboratory (Lucey et 
al., 2009; Marquis, 2011). Coined as the first human cell line, HeLa cells were 
isolated from a cancerous cervical lesion biopsy of Henrietta Lacks (Lucey et al., 
2009).  These cells grew robustly and were naturally immortal because the 
patient was infected with papillomavirus (HPV) (Lucey et al., 2009).  Isolated 
within the tissue culture laboratory at Johns Hopkins University, HeLa cells were 
quickly sent to laboratories throughout the world for studying a multitude of 
diseases (Lucey et al., 2009).  HeLa cells caused a historic change in the 
scientific community, yet the isolation of human cells quickly became a 
controversial subject.  By 2013, Nature News reported that HeLa cells 
contributed to more than 60,000 research papers and, most notably, to the 
development of the polio vaccine in 1952 (Marquis, 2011; Callaway, 2013).   
Today there are thousands of cell lines available for laboratory use.  At the 
International Tissue Culture meeting in 1957, nomenclature of cell strains was 
discussed and a general guideline created (Nomenclature of Cell Strains, 1958).  
Cell nomenclature is no longer based on the patient’s name where the cells 
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originated from (e.g. HeLa from Henrietta Lacks), but rather can be termed for 
the cell type (i.e. HepG2 isolated from a liver hepatocellular carcinoma).  Still 
today, discussion on nomenclature of newly described cell types such as stem 
cell lines continues (Luong et al., 2011).   
Selection of a cell line to use for in vitro experiments should be well 
thought-out.  There are many characteristics to consider including species, type 
of cell, receptors expressed, and cytokines produced.  Multiple passages of a cell 
line can alter these characteristics.  For instance, it has been noted that Vero 
cells can become tumorigenic after too many passages (Marquis, 2011).  
Therefore, a primary cell line may be advantageous, if obtainable.   
Primary cultures, those that have not been sub-cultured, are useful for 
studying any number of diseases in vitro, but their sometimes poor stability, low 
survivability, improper differentiation, and low obtainable cell number make them 
difficult to use for experimentation (Allen et al., 2005).  Immortalized cell lines are 
therefore commonly used for in vitro studies.  A multitude of cell lines and 
information about each line are available through American Type Culture 
Collection (ATCC).  Specifically, many human epithelial cells are regularly used 
in research and available through ATCC: A549, Caco2, HeLa, MCF7, HEp-2, and 
HepG2 cells.  Unlike these cell lines, the HEK-293 and BEAS-2B cells are 
normal, noncancerous epithelial cell lines.  HEK-293 are human embryonic 
kidney cells.  Kidney epithelial cells are not the most physiologically relevant cell 
line to use for studying respiratory infections.  Because the lung epithelium is 
where PIV-3 naturally infects, the human lung bronchial epithelial cells, BEAS-
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2B, are a good model system for studying PIV-3 in vitro.  Few bovine cell lines 
are available.  Because a bovine lung epithelial cell line is not available, Madin-
Darby Bovine Kidney (MDBK) epithelial cells are the best option obtainable for 
studying PIV-3 in a bovine in vitro cell culture model.   
Vero cells are one of the most commonly used and cited cell lines in 
research (Ammerman et al., 2008).  Originally described in 1963 by Yasumura 
and Kawakita, Vero cells are an African Green Monkey kidney epithelial cell line 
named for the French terms VerdE (green) and RenO (kidney).  Vero cells are 
easy to handle, grow rapidly, and are an extremely common cell type for viral 
propagation and in vitro viral infections (Nahapetian et al., 1986; Ammerman et 
al., 2008, Marquis, 2011).  Also, a wide range of viruses grow well in Vero cells, 
but this is because Vero cells do not produce type I IFNs (Emeny and Morgan, 
1979).  Because Vero cells are type I IFN-deficient, they may not be the most 
biologically relevant cell type for studying viral infections.  However, for the 
purpose the studies described herein, we used Vero cells as a model for studying 
type III IFNs independent of type I IFNs.   
 
Cytokines produced in response to viral infection  
Interferons (IFNs) are a class of cytokines named for their function: to 
“interfere” with viral replication.  Type I IFNs (IFN-α, -β, -ε, -κ, -ω, -τ, -δ, -ζ) were 
discovered in 1957 by Isaacs and Lindenmann.  Depicted in the left cell of Figure 
2, a series of events leads up to IFN production can be triggered by a number of 
viral sensors.  RIG-I like receptors (RLRs) including retinoic acid-inducible gene 1 
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(RIG-I) and melanoma differentiation-associated protein 5 (MDA5) recognize 
uncapped 5’ triphosphorylated ssRNA and short dsRNA, or long dsRNA, 
respectively (Hornung et al., 2006; Pichlmair et al., 2006 and 2009).  Caspase 
activation and recruitment domains (CARD) on MDA5 and RIG-I interact with 
mitochondrial antiviral-signaling protein (MAVS) (also known as virus-induced 
signaling adapter (VISA), interferon promoter-stimulating factor-1 (IPS-1), or 
Cardif) (Loo et al., 2008).  Recognition of specific RNA by these pattern 
recognition receptors (PRRs) leads to IFN regulatory factors (IRF)-3 and -7 
binding to the promoter region to induce IFN production. Furthermore, toll-like 
receptors (TLRs)-3, -7, -8, and -9, recognize dsRNA, ssRNA, G-rich nucleotides, 
and unmethylated CpG DNA, respectively (Botos et al., 2011).  A MyD88-
dependent (or in the case of TLR3, a MyD88-independent, TRIF-dependent) 
signaling cascade occurs which phosphorylates inhibitor of kappa B (I-κB) to 
degrade it and release nuclear factor kappa-light-chain-enhancer of activated B 
cells (NFκB) which translocates into the nucleus for proinflammatory and IFN 
cytokine production (McCartney and Colonna, 2009).  Synthetic agonists of any 
of the TLRs are commercially available and typically used as a positive control.  
For instance, the dsRNA analog, polyinosinic:polycytidylic acid (Poly I:C), 
stimulates TLR3 (Matsumoto and Seya, 2008).  Imiquimod, a guanosine analog, 
activates TLR7 (González‐Navajas et al., 2012).  The TLR-independent 
simulation, phorbol myristate acetate (PMA) with ionomycin is commonly used to 
enhance cytokine production in a cell.  The calcium ionophore, ionomycin, 
stimulates calcium release while PMA activates protein kinase C (PKC) (Zhang 
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and O’Neil, 1999).  Viral dsRNA can also be initially recognized by protein kinase 
R (PKR).  PKR activation leads to eukaryotic initiation factor 2 (eIF2α) 
phosphorylation, which in turn halts translation in the cell.  Activation of PKR also 
leads to induction of gene transcription, including proinflammatory cytokines and 
IFNs. 
 
 
 
Figure 2.  Antiviral signaling cascade in epithelial cells from recognition of 
viral genetic material to production of downstream antiviral molecules. 
As seen in the left epithelial cell, viral RNA can be recognized by acid-inducible 
gene 1 (RIG-I) and melanoma differentiation-associated protein 5 
(MDA5)Caspase activation and recruitment domains (CARD) on MDA5 and RIG-
I interact with mitochondrial antiviral-signaling protein (MAVS).  This leads to IFN 
regulatory factors (IRF)-3 and -7 binding to induce IFN production.  Toll-like 
receptors (TLRs)-3, -7, -8, and -9 can also recognize viral RNA/DNA to cause 
phosphorylation of inhibitor of kappa B (I-κB), which degrades to release nuclear 
factor kappa-light-chain-enhancer of activated B cells (NFκB) into the nucleus to 
produce proinflammatory (proinflam.) cytokines and type I and III interferons 
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(IFNs).  The right cell depicts IFNs binding to their cognate heterodimeric 
receptor.  Type I IFNs bind to the IFNAR1 and IFNAR2, while the type III IFN 
receptor is comprised of IFN-λR1 and IL-10R2.  Upon receptor binding, the 
Janus kinase/signal transducers and activators of transcription (JAK/STAT) 
pathway is activated.  Kinases Tyk2 (tyrosine kinase 2) and Jak1 phosphorylate 
Stat1 and 2.  Upon phosphorylation, Stat1 and 2 can then heterodimerize and 
join with IRF9 to bind the IFN-sensitive response element (ISRE).  This causes 
production of many antiviral molecules whose role is to control viral propagation.  
Homodimerization of Stat1 can also occur which forms IFN-α activated factor 
(AAF) and binds to the IFN-γ activated sequence (GAS) to produce IFN 
regulatory factor 1 (IRF1).  
 
 
Expressed by nearly all cell types, the class II heterodimeric IFN α/β 
receptor (IFNAR1/2) on neighboring cells binds type I IFNs (Taniguchi and 
Takaoka, 2001; Pestka, 2007; González‐Navajas et al., 2012).  The signaling 
cascade that follows IFNs binding to their respective receptors can be seen in the 
right cell in Figure 2.  The common Janus kinase/signal transducers and 
activators of transcription (JAK/STAT) pathway occurs upon receptor binding 
(Rawlings et al., 2004; González‐Navajas et al., 2012).  Receptor tyrosine kinase 
2 (Tyk2) and Jak1, associated with IFNAR1 and IFNAR2 respectively, are  
docking sites for tyrosine phosphorylation of Stat1 and Stat2 (Taniguchi and 
Takaoka, 2000 and 2001).  Stat1 and Stat2 heterodimerize and bind to IRF9; this 
forms IFN-stimulated gene factor 3 (ISGF3).  ISGF3 enters the nucleus to turn on 
genes for viral inhibition.  Stat1 can also homodimerize to create IFN-α activated 
factor (AAF) (Taniguchi and Takaoka, 2000 and 2001).  AAF binds to the IFN-γ 
activated site (GAS) to produce IRF1. These genes include Myxovirus resistance 
gene A (MxA), 2′,5′-Oligoadenylate Synthetase (OAS), IFN-stimulated genes 
(ISGs), and PKR (Sadler and Williams, 2008).  The GTPase MxA may block 
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nuclear transport of the virus (Kochs and Haller, 1999) and suppress viral 
replication (Matzinger et al., 2013).  OAS leads to activation of RNase L to 
degrade viral RNA (Silverman, 2007).  This degraded RNA can then activate 
RIG-I/MDA5 for further IFN induction (Sadler and Williams, 2008).  ISG56, also 
known as IFN-induced protein with tetratricopeptide repeats 1 (IFIT1), has 
specifically been shown to restrict replication of PIV-5 (Andrejeva et al., 2013).  
ISG56 produces P56 family proteins, which have a number of functions in 
blocking the virus (Fensterl and Sen, 2011).  The most well characterized of 
these functions include binding eIF3 to inhibit translation. 
Type III IFNs were discovered simultaneously by two groups and 
published in the same issue of Nature Immunology in 2003 (Kotenko et al., 2003; 
Sheppard et al., 2003).  Sergei Kotenko termed these novel cytokines IFN-λ1, 
IFN- λ2, IFN-λ3, while Paul Sheppard referred to them as interleukin (IL)-29, IL-
28A, and IL-28B (Uzé and Monneron, 2007; Donnelly and Kotenko, 2010).  IFN-
λ2 and -λ3 share 96% homology; IFN-λ1 and -λ2 are 81% identical (Kotenko et 
al., 2003; Sheppard et al., 2003; Uzé and Monneron, 2007).  Structural analyses 
determined the close relationship between IL-10 family cytokine and type III 
IFNs; based on their crystal structure, type III IFNs are more similar to the IL-10 
family than type I IFNs (Gad et al., 2010; Hamming et al., 2010).  All three IFN-λs 
have been identified in humans, mice, swine, and chickens (Kotenko et al., 2003; 
Sheppard et al., 2003; Karpala et al., 2008; Sang et al., 2010).  Santos and 
colleagues have characterized bovine IFN-λ3 (boIFN-λ3) (Segundo et al., 2011; 
Perez-Martin et al., 2012).  In mice, the IFN-λ1 gene is mutated and therefore a 
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pseudogene that does not encode a functional protein (Donnelly and Kotenko, 
2010). 
Redundancy exists between type I and type III IFNs, but there are some 
noticeable differences.  The gene encoding IFN-λs has multiple exons, which is 
in contrast to the type I IFN gene that is intronless (Uzé and Monneron, 2007; 
Donnelly and Kotenko, 2010).  Along with type I IFNS, IFN-λs are induced by 
PRRs including, TLR, RIG-I/MDA5, and PKR (Iversen and Paludan, 2010).  
Some in vitro evidence shows that IFN-α pretreatment in epithelial cells is 
necessary to enhance TLR3 stimulation by Poly (I:C) and type III IFN gene 
expression (Sirén et al., 2005; Tissari et al., 2005).  The promoter region of IFN-
β, requires the coordination and cooperative assembly of an enhancesome 
containing NFκB and IRF3/7 (Thomson et al., 2009).  In contrast, a more flexible 
enhancer model was found for the IFN-λ1 promoter (Thomson et al., 2009).  That 
is, spatially separated promoter elements, NFκB and IRF3/7, can independently 
regulate gene expression.  Most distinctively, the type III IFN receptor is a class II 
heterodimer composed of IFN-λR1/IL-28RA and IL-10R2 (Donnelly and Kotenko, 
2010).  In contrast to the ubiquitously expressed type I receptor, the IFN-λR1 is 
found primarily on epithelial cells and plasmacytoid dendritic cells (pDCs) (Li et 
al., 2009; Sommereyns et al., 2008).  Due to differential spicing of the IFN-λR1 
mRNA transcript, 3 splice variants exist; these splice variants can produce 
secreted soluble protein, full-length membrane associate IFN-λR1 protein, and a 
membrane bound receptor that cannot signal properly due to a shorter 
cytoplasmic domain (Witte et al., 2009; Donnelly and Kotenko, 2010).  This is 
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nearly identical to the type I IFN receptor where multiple splice variants have 
been identified to generate three isoforms of IFNAR2 (de Weerd et al., 2007). 
Similar to type I IFNs, a JAK/STAT signaling pathway has been found to be 
induced upon IFN-λ binding its respective receptor (Uzé and Monneron, 2007; 
Zhou et al., 2007; Donnelly and Kotenko, 2010).  Though these cytokines have 
several redundant functions in the cell, it is thought that the IFN-β and IFN-λ 
promoters evolved independently of one another (Li et al., 2009; Thomson et al., 
2009).   
Type I IFNs as a therapeutic treatment modality are used in healthcare 
today, but there are many adverse side effects associated with the treatment 
(Pestka, 2007).  Due to their similar function, but more directed target, the use of 
IFN-λs as a therapeutic is beginning to be adopted (Donnelly et al., 2011).  That 
is, restricted expression of the IFN-λR1/IL-28RA is noted to be an important 
difference between type I and III IFNs and may aid in understanding the 
important role of type III IFNs in, especially, viral infections as the epithelial cells 
are among the first cells to encounter a virus during infection (Gad et al., 2010).  
Specifically, during respiratory virus infection, nasal epithelial cells secrete a 
higher proportion of type III IFNs and little type I IFNs (Okabayashi et al., 2011).  
In other cell types and various viral infections, both IFN-α/β and IFN-λs can be 
secreted simultaneously (Chi et al., 2006; Li et al., 2009; Okabayashi et al., 
2011). 
It is well known that type I IFNs have antiviral activity and many viruses 
have a means of blocking IFN induction.  Paramyxoviruses can create a 
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V/W/D/C/Y accessory protein based off of RNA-editing that inserts one or two 
guanines into the P gene or by alternative initiation codons in the case of C and 
Y proteins (Goodbourn and Randall, 2009).  These accessory proteins can block 
any protein involved in induction of IFN-α/β from MDA5 and RIG-I to IRF and 
NFκB and anything in between (Figure 3 in Goodbourn and Randall, 2009; Motz 
et al., 2013).  The V protein of many paramyxoviruses has been shown to inhibit 
RNA helicase activity of both MDA5-dependent and RIG-I-dependent IFN 
induction (Andrejeva et al., 2004; Childs et al., 2009; Childs et al., 2012; Motz et 
al., 2013).  Also, the V protein produced during PIV-2 infection has been shown 
to inhibit TRAF6 mediated ubiquitination of IRF7 to prevent activation of IFN 
induction through TLR-7/9 (Kitagawa et al., 2013).  The C protein encoded by 
HPIV-1 was shown to form a complex with Stat1 and retain Stat within the 
perinuclear space to therefore block the antiviral response (Schomacker et al., 
2012).  Many groups have described how the nonstructural proteins (NS1 and 
NS2) of RSV play a role in suppression of type I IFN production and downstream 
signaling during infection (Bossert et al., 2003; Elliott et al., 2007; Ramaswamy et 
al., 2006; Spann et al., 2004).  Few papers have been published on the in vitro 
treatment of IFN-λs during viral infections, none of them during PIV infection 
(Almeida et al., 2008; Ank et al., 2008; Stoltz and Klingström, 2010; Zhang et al., 
2011). 
Also depicted in Figure 2, in addition to production of IFNs, pro-
inflammatory cytokines are induced in response to viral infection.  Each pro-
inflammatory cytokine produced plays an important role in aiding in infection.  
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Monocyte and macrophage recruitment to the lung is accomplished by 
production of IL-1β, macrophage inflammatory protein 1 alpha (MIP-1α), 
monocyte chemoattractant protein 1 (MCP-1), and tumor necrosis factor alpha 
(TNF-α) (Vareille et al., 2011).  The chemokine CXCL8/IL-8 is primarily produced 
by epithelium to recruit neutrophils to the lung during respiratory infections 
(Vareille et al., 2011).  IL-6 is involved in the switch from neutrophil attraction to 
monocyte/macrophages recruitment (Hurst et al., 2001; Scheller et al., 2011).  IL-
6 has also been shown to have antiviral properties, but this is not surprising 
because the IL-6 receptor involves JAK/STAT signaling cascade similar to that 
seen downstream of type I and III IFN receptors (Trinchieri, 2010; Wong et al., 
2003).   
 
Phosphoproteomics 
 Proteomics, the large-scale study of proteins in a system, is a useful tool 
for studying viral-host interactions and has applications in clinical virology 
(Kunec, 2013; Mancone et al., 2013).  It is thought that up to 50% of all proteins 
are regulated by protein kinases (Hjerrild and Gammeltoft, 2006).  To examine 
signal transduction pathways, mass spectrometry (MS) based 
phosphoproteomics has emerged (Schreiber et al., 2008).  That is, signal 
transduction is regulated through a phosphorylation cascade where phospho- 
groups are added or removed from proteins by kinases or phosphatases, 
respectively (Rigbolt and Blagoev, 2012).  The specific steps of phosphopeptide 
isolation to protein identification must be determined based on the system of 
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interest (Schreiber et al., 2008; Nilsson, 2012).  Due to the low abundance of 
phosphopeptides, the addition of an enrichment step is not only necessary, but  
the key difference between conventional proteomics and phosphoproteomics 
(Dunn et al., 2010; Montoya et al., 2011, Beltran and Cutillas, 2012, Schreiber et 
al., 2008; Engholm-Keller and Larsen, 2013).  A combination of one or more 
techniques for selectively enriching or concentrating phosphopeptides is used: 
immobilized metal affinity chromatography (IMAC) or metal oxide affinity 
chromatography (MOAC), antibody-based affinity purification, chemical 
derivatization, and chromatography (Beltran and Cutillas, 2012).  IMAC uses 
transition metal ions to bind the electron donor of a protein; most commonly, 
Fe(III)-nitrilotriacetate (NTA) is used to preferentially bind oxygen-rich portions of 
phosphate groups (Gaberc-Porekar and Menart, 2001; Dunn et al., 2010).  A 
newer and more selective technique, MOAC, uses TiO2 or ZrO2 resin to 
selectively enrich for phosphorylated peptides (Pinkse et al., 2004; Montoya et 
al., 2011; Beltran and Cutillas, 2012).  TiO2-MOAC was found to be more efficient 
at recovering multiply phosphorylated peptides than ZrO2-MOAC and more 
specific to phosphopeptide enrichment as compared to IMAC (Aryal and Ross, 
2010).  Antibodies specific to phosphorylated serine (pS) and threonine (pT) for 
phosphopeptide selection may not be suitable for the system in question, i.e. no 
antibodies available for the species of interest or lack of performance for 
immunopreciptation (Beltran and Cutillas, 2012; Grønborg et al., 2002).  
Chemical derivatization selectively modifies the phosphate group, commonly β-
elimination of the phosphate followed by Michael addition of a more stable 
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chemical group (Adamczyk et al., 2001; Thaler et al., 2003; Beltran and Cutillas, 
2012).  Finally, strong cation/anion exchange (SCX or SAX) chromatography, 
both of which separate proteins based on charge, may be useful (Nühse et al., 
2003; Beausoleil et al., 2004; Beltran and Cutillas, 2012).  Coupling any of these 
techniques may be beneficial, but loss of product may also occur due to repeated 
use (depicted in Figure 1 in Beltran and Cutillas, 2012).  Quantification of these 
enriched phosphopeptides is then employed through, most commonly, stable 
isotope labeling of amino acids (SILAC) or isobaric tags for relative and absolute 
quantitation (iTRAQ) (Wang et al., 2011; Schreiber et al., 2008; Engholm-Keller 
and Larsen, 2013). 
 The use of phosphoproteomics has been employed in a vast number of 
systems, especially examining changes during cancer and disease (Najam-ul-
Haq et al., 2012).  Little has been studied on the phosphoproteome during viral 
infections.  The proteome and phosphoproteome has been evaluated in embryo 
fibroblasts infected with multiple strains of Marek’s Disease virus (Chien et al., 
2011 and 2012).  Normal rat kidney cells were subject to Rous sarcoma-virus 
infection under temperature-sensitive conditions and the phosphoproteins 
differences examined for early diagnosis and therapeutic manipulation potential 
(Yamaoka et al., 2006).  The phosphoproteome was found to partake in a vast 
remodeling upon HIV-1 entry into human CD4+ T cells (Wojcechowskyj et al., 
2013).  Interestingly, the phosphoproteome of the Adenovirus type 2 virion 
structural proteins were evaluated due to their potential important role during 
infection (Bergström Lind et al., 2012).  Similarly, 36 novel phosphorylation sites 
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were found in Influenza A and B viral proteins; the conservation of 
phosphorylation at these sites may be potential targets for antiviral therapy 
(Hutchinson et al., 2012). 
 
Hypothesis and Aims 
 
 This dissertation aims at examining immunological response(s) to PIV-3 
infection using in vitro cell culture systems.  Based on previous publications, 
TtPIV-1 was found to be similar to, but distinct from, both human and bovine PIV-
3 isolates.  These initial findings were based only upon partial sequences of the F 
and HN viral genes.  In Chapter 2 TtPIV-1 is further characterized on cytokine 
production, viral growth over time, and full genome sequencing as compared to 
BPIV-3 and HPIV-3.  Chapter 3 is aimed at examining the type III IFN response 
during TtPIV-1, BPIV-3, and HPIV-3 infection.  Because paramyxoviruses are 
known to affect many stages of the type I IFN pathway, it was hypothesized that 
host cells could utilize type III IFNs during PIV-3 infection to circumvent the 
downregulation of type I IFNs.  Vero cells were used as a natural tool to examine 
type III IFN signaling pathways independent of type I IFNs.  Finally, Chapter 4 
uses phosphoproteomics for the large-scale examination of signaling pathways 
that are affected early in PIV-3 infections.   
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Abstract 
 
Parainfluenza virus 3 (PIV-3) is a common viral infection not only in 
humans, but many other species.  Serological evidence suggests that nearly 
100% of children in the United States have been infected with PIV-3 by five years 
of age.  Similarly, in cattle PIV-3 is commonly associated with bovine respiratory 
disease complex (BRDC).  A novel dolphin PIV-3 (TtPIV-1) was described by 
Nollens et al. in 2008 from a dolphin that was diagnosed with an unknown 
respiratory illness.  At that time, TtPIV-1 was found to be most similar to, but 
distinct from, bovine PIV-3 (BPIV-3).  In the present study, similar viral growth 
kinetics and pro-inflammatory cytokine (IL-1β, IL-6, and CXCL8) production were 
seen between BPIV-3 and TtPIV-1 in BEAS-2B, MDBK, and Vero cell lines.  
Initial nomenclature of TtPIV-1 was based on partial sequence of the fusion and 
RNA polymerase genes.  Based on the similarities we saw with the in vitro work, 
it was important to examine the TtPIV-1 genome in more detail.  Full genome 
sequencing and subsequent phylogenetic analysis revealed that all six viral 
genes of TtPIV-1 clustered within the recently described BPIV-3 genotype B 
strains and it is proposed that TtPIV-1 be re-classified with BPIV-3 genotype B 
strains.   
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Introduction 
 
Parainfluenza virus 3 (PIV-3) is a member of the Paramyxoviridae family 
and genus Respirovirus [1].  This family consists of single-stranded negative 
sense RNA viruses that are non-segmented.  PIV-3 is a prominent cause of 
pneumonia and bronchiolitis in children and infants [2]. Seroepidemiology 
indicates that nearly 100% of children in the United States have been infected 
with PIV-3 by the age of five [3].  PIV can infect many species including humans, 
dogs, cattle, non-human primates, sheep, goats, bison, guinea pigs, rhinoceros, 
moose, and camels [4].  In cattle, PIV-3 is a common contributor to bovine 
respiratory disease complex (BRDC) [5].  Isolated from a bottlenose dolphin that 
was diagnosed with an unknown respiratory illness, TtPIV-1 (Tursiops truncatus 
parainfluenza virus type 1) was first described in 2008 by Nollens et al [6].  The 
novel TtPIV-1 was originally characterized on the basis of sequence analysis 
using genomic fragments of the fusion (F) and large RNA polymerase (L).  Data 
available at the time suggested that TtPIV-1 and bovine PIV-3 (BPIV-3) arose 
from a common ancestor but were genetically distinct [6].  A subsequent 
seroprevalence study found that PIV in marine mammals is common and 
seroconversion occurred in 22 out of 114 bottlenose dolphins (32%) [7].  
Epithelial cells represent a first line of defense in response to respiratory 
viral infections.  Pro-inflammatory molecules, including cytokines and 
chemokines, secreted by epithelial cells among others, are important for viral 
clearance, but excessive production of these mediators can be detrimental and 
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contribute to disease pathology.  Toll-like receptors (TLRs) expressed by 
epithelial cells sense virus-associated molecular patterns to induce expression of 
specific cytokines that play important roles in the innate immune response [8].  
Inflammatory mediators, including interleukin-1β (IL-1β), IL-6, and CXCL8 (IL-8) 
have a noted role during respiratory viral infections [9].  These cytokines recruit 
and activate inflammatory cells critical in the response to infection and viral 
clearance.  For example, the chemotactic peptide, CXCL8, causes neutrophil 
activation and degranulation.  IL-1β modulates adhesion molecule expression on 
endothelial cells and therefore regulates leukocyte emigration into tissues [10].  
Together with other pro-inflammatory mediators, IL-6 classically initiates the 
acute phase response and activates leukocytes.  In addition, IL-6 plays a pivotal 
role in bridging innate and acquired immune responses [11].  Since IL-1β, IL-6, 
and CXCL8 are secreted at high levels during respiratory viral infections, their 
induction likely contributes to the pathophysiology seen in patients [3, 8, 12-15]. 
The present study compared TtPIV-1 to representative bovine and human 
PIV-3 strains with respect to viral growth kinetics and the ability to induce pro-
inflammatory cytokine expression in host-specific epithelial cell lines.  TtPIV-1 
had similar viral growth patterns to BPIV-3 and induction of pro-inflammatory 
cytokine mRNA levels was similar and more limited for TtPIV-1 and BPIV-3 
infection, compared to the HPIV-3.  Whole genome sequencing of TtPIV-1 was 
performed to fully confirm the virus’ classification.  Based on the sequencing 
results presented herein, TtPIV-1 is phylogenetically similar to the BPIV-3b 
isolates and we propose that TtPIV-1 be classified as a BPIV-3 genotype B.   
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Materials and Methods 
 
Cell culture and media recipes 
Multiple epithelial cells were used through the study.  BEAS-2B (ATCC, 
CRL-9609) were grown as per ATCC’s recommendations.  Briefly, flasks were 
coated in 0.01 mg/mL fibronectin (Corning, 356008), 0.03mg/mL bovine collagen 
type I (Advanced Biomatrix, 5005-B), and 0.01 mg/mL bovine serum albumin 
(BSA) (Sigma, A3059).  Bronchial Epithelial Cell Growth Medium (BEGM) did not 
contain any antibiotics or antimycotics, but was supplemented with growth factors 
(Lonza, CC-3170).  Vero cells (ATCC, CCL-81) were grown in Eagle’s Minimum 
Essential Medium (EMEM) (ATCC, 30-2003) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (PAA, A11-265) and 1x antibiotic-
antimycotic (Sigma, A5955).  MDBK-A were grown in Minimum Essential Media 
(MEM) supplemented with heat-inactivated 10% FBS, L-glutamine (gibco, 
25030), and 1x antibiotic-antimycotic.  All cells were grown at 37oC in 5% CO2.   
 
Virus strains 
Bovine parainfluenza virus 3 strain SF-4 was purchased from ATCC (VR-
281).  The dolphin isolate of Parainfluenza Virus (TtPIV-1) was acquired from the 
Marine Mammal Health Program at the University of Florida [6].  Both BPIV-3 
and TtPIV-1 were grown in primary bovine turbinate (BT) cells.  The Human 
parainfluenza virus 3 C243 strain used was purchased from ATCC (VR-93).   
HPIV-3 was propagated in Vero cells. 
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In vitro treatment with virus or positive control 
Cells incubated with virus at a multiplicity of infection (MOI) of 2 with no 
serum, if applicable, for one hour.  After the hour, virus and media were removed 
and fresh medium, with serum if applicable, was replenished for the remainder of 
the incubation.  A positive control for cytokine induction included 20 ug/mL 
polyinosinic-polycytidylic acid (poly I:C) (Sigma, P1530) or 1 ug/mL phorbol 12-
myristate 13-acetate (PMA) (Sigma, P1585) with 500 ng/mL ionomycin (Life 
Technologies, I24222).  Cells were incubated for 10 minutes with the positive 
control and 0.6 or 6% Lipofectamine 3000 (Invitrogen, L3000-015).  The BEAS-
2B were treated with 0.6% Lipofectamine 3000 versus 6% in the Vero and MDBK 
cells.  After 10 minutes, the treatment was discarded and the monolayer washed 
once with medium to remove any residual Lipofectamine 3000 [16].  Complete 
medium was added to all wells for the remainder of the culture period. 
 
RNA extraction and cDNA synthesis 
Samples were collected in RLT Lysis Buffer (QIAGEN, 1015762) and 2-
beta-mercaptoethanol (2-ME) (Sigma, BP176).  Total RNA was isolated using the 
RNeasy MINI RNA Isolation Kit (QIAGEN, 74106) per the manufactures protocol.  
DNase digestion was achieved using the QIAGEN RNase-Free DNase Set 
(79254).  After elution, RNaseOUT (Invitrogen, 10777) was added to each 
sample.  Eluted RNA was transcribed using Random Primers (Invitrogen, 48190) 
and dNTP Mix (Invitrogen, 18427) followed by 5X First-Strand Buffer, 0.1 M DTT, 
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and Superscript III Reverse Transcriptase (Invitrogen, 18080) per the 
manufactures instructions.   
 
Real-time PCR  
Briefly, Power SYBR Green PCR Master Mix (Invitrogen, 4367659) was 
added to 10 µM of both the forward and reverse primer (Integrated DNA 
Technologies), dH2O, and cDNA template.  The amplification conditions for all 
sequences were: 95oC for 10 minutes, followed by 40 cycles of 95oC for 15 
seconds and 60oC for 1 minute, and a final dissociation step.  Plates were run on 
an Applied Biosystems 7300 Real-Time PCR System.  Relative gene expression 
was determined using the 2-ΔΔCt method [17].  GAPDH was used as a reference 
gene for the Vero cells and BEAS-2B, while RPS9 was used as the 
housekeeping gene for MDBK cells [18].  All primer sequences are listed in Table 
1.   
 
Table 1  Forward and reverse primer sequences used in real-time PCR assays 
 
Viral Titers 
Viral titers were measured using a microtiter assay.  Briefly, virus was 
grown for a given amount of time and freeze-thawed to allow for cell lysis and 
Target Gene Nucleotide Sequence Forward Nucleotide Sequence Reverse Citation 
IL-1β (human) CCT GTC CTG CGT GTT GAA AGA GGG AAC TGG GCA GAC TCA AA Boeuf, et al. [52] 
IL-1β (bovine) TTC TGT GTG ACG CAC CCG TGC AGC ACA CAT GGG CTA GCC AGC Sacco, et al. [53] 
IL-6 (human) CAC AGA CAG CCA CTC ACC TC TTT TCT GCC AGT GCC TCT TT Hinzey, et al. [54] 
IL-6 (bovine) CTG AAG CAA AAG ATC GCA GAT CTA CTC GTT TGA AGA CTG CAT CTT CTC Sacco, et al. [53] 
IL-8 (human) AGT TTT TGA AGA GGG CTG AGA AT CAA CAG ACC CAC ACA ATA CAT GA Hinzey, et al. [54] 
IL-8 (bovine) CGC TGG ACA GCA GAG CTC ACA AG GCC AAG AGA GCA ACA GCC AGC T Sacco, et al. [53] 
GAPDH ACT TTG GTA TCG TGG AAG GAC T GTA GAG GCA GGG ATG ATG TTC T Hinzey, et al. [54] 
RPS9 CGC CTC GAC CAA GAG CTG AAG CCT CCA GAC CTC ACG TTT GTT CC Sacco, et al. [53] 
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subsequent viral release.  Serial dilutions were prepared of freeze-thawed 
samples in serum-free EMEM supplemented with antibiotic-antimycotic.  All 
microtiter plate assays were performed using Vero cells.  Microtiter plates were 
allowed to incubate for 6-7 days at 37oC in 5% CO2.  An endpoint titer in units of 
TCID50/mL was calculated using the Reed-Muench method [19]. 
 
Sequencing 
The TtPIV-1 genome was sequenced using a random primed, barcoded 
protocol on the Ion Torrent platform for sequencing multiple viral genomes 
simultaneously as previously described by Neill et al. [20].   
 
Phylogenetic analysis 
Phylogenetic analysis was performed on multiple isolates of PIV-3: HPIV-3 
JS (Z11575), BPIV-3 Kansas (AF178654), HPIV-3 14702 (EU424062), HPIV-3 
LZ22 (FJ455842), BPIV-3 SF-4 (AF178655), BPIV-3 Q5592 (EU277658), BPIV-3 
12Q061 (JX969001), BPIV-3 SK217 (BPU31671), BPIV-3 NIH 47885 (PIFM), 
BPIV-3 SD0811 (HQ530159), and HPIV-3 C243 (EU346887).  Sequences were 
aligned using ClustalW.  Phylogenetic trees using MacVector and were produced 
using a UPGMA best tree method with Tamura-Nei distance.  Sequences above 
were translated using MacVector and/or protein sequences were acquired 
through GenBank for protein alignment: HPIV-3 F (AAB21447), BPIV-3 F 
(AF178854), HPIV-3 HN (ACF28542), BPIV-3 HN (BAM72627), HPIV-3 L 
(AAB48690), BPIV-3 L (BAM72628), HPIV-3 M (AAB48687), BPIV-3 M 
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(BAM72625), HPIV-3 N (AAA46864), and BPIV-3 N (BAM72623).  Protein 
alignment was conducted using ClustalW and sequences conserved sequences 
compared. 
 
Results 
 
Kinetics of TtPIV-1, BPIV-3, HPIV-3 viral growth in Vero, MDBK, and BEAS-
2B cell lines  
Three epithelial cell lines were chosen to compare differences in host-
specificity of the viruses.  A human bronchial epithelial cell line (BEAS-2B) and 
Madin-Darby Bovine Kidney (MDBK) cells were used for host specific 
comparisons.  Vero cells were selected because of their frequent use as an 
epithelial cell in the laboratory and were in fact used in the original isolation of 
TtPIV-1 [6].  Based on electron microscopy (EM), growth kinetics of TtPIV-1 was 
most similar to BPIV-3 in Vero, MDBK, and BEAS-2B cells (data not shown).  
Microtiter plate assays were used to measure viral replication over time (Fig. 1).  
The three viruses grew to a similar titer by 48 hours in all three cell types.  It is 
important to note the variable early growth pattern in MDBK and BEAS-2B cell 
lines.  HPIV-3 growth is significantly delayed as compared to TtPIV-1 and BPIV-3 
in MDBK cells.  The reverse is true in the BEAS-2B cells where BPIV-3 and 
TtPIV-1 growth is significantly slower than the HPIV-3 early in infection.   
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Fig. 1  Kinetics of TtPIV-1, BPIV-3, HPIV-
3 viral titers in Vero, MDBK, and BEAS-
2B cell lines using a microtiter plate 
assay.   
Cells were inoculated with TtPIV-1, BPIV-
3, or HPIV-3 at an MOI of 2 for a 6, 12, 
24, 48, or 72 hours.  Titer plates were set 
at serial dilutions in serum-free media for 
6-7 days and a TCID50 was calculated.  
All results are expressed as log(titer) and 
error bars represent SEM.  A Bonferroni 
post test was conducted in Prism where 
p<0.05 was considered significant.  
Differing superscripts (a, b) denote 
statistically significant differences in 
log(titer) 
 
 
 
 
 
 
 
 
Pro-inflammatory cytokine expression profile in Vero, MDBK, and BEAS-2B 
cell lines inoculated with TtPIV-1, BPIV-3, and HPIV-3  
Epithelial cells are known to induce pro-inflammatory cytokines in 
response to viral infection.  Here we examined, for the first time, the induction of 
pro-inflammatory cytokines in response to TtPIV-1 infection as compared to 
those produced by epithelial cells infected with BPIV-3 and HPIV-3.  Distinct 
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differences in pro-inflammatory cytokine expression were noted between the 
viruses as observed by real-time PCR during a viral time course in vitro (Fig. 2).  
In BEAS-2B cells, a potent response was seen during HPIV-3 infection in all 
three cytokines; IL-1β, IL-6, and CXCL8 expression was significantly upregulated 
in response to HPIV-3 at 24 and 48 hours post infection.  In MDBK cells, IL-6 
was significantly increased at 24 and 48 hours post infection with HPIV-3.  By 48 
hours post infection, CXCL8 was significantly increased in the MDBK cells with 
all three viruses.  The Vero cells did express significant amount of IL-6 during a 
HPIV-3 infection as early as 6 hours.  By 24 hours post infection, CXCL8 
expression is upregulated in the Vero cells and continued to be expressed 
through 48 hours with all three viruses.  In Vero cells, IL-1β and IL-6 were also 
upregulated at 48 hours post infection with HPIV-3 only.  One may have 
expected to see host-specific differences, for example the HPIV-3 would be 
predicted to produce distinct cytokine expression in the human cell line, but this 
does not seem to be the case.  Overall, the HPIV-3 infection induced a robust 
pro-inflammatory cytokine response in all three cell types, while the TtPIV-1 and 
BPIV-3 induced limited cytokine expression.   
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Fig. 2  Pro-inflammatory cytokine expression profile in Vero, MDBK, and BEAS-
2B cell lines inoculated with TtPIV-1, BPIV-3, and HPIV-3 at an MOI of 2.   
Cytokine expression was measured by real-time PCR.  In Vero and BEAS-2B 
cells, a 10 minute treatment of 20 ug/mL Poly I:C with either 6% or 0.6% 
Lipofectamine 3000, respectively, was used as a positive control.  In MDBK cells, 
1 ug/mL PMA and 500 ng/mL ionomycin with 6% Lipofectamine 3000 for 10 
minutes served as a positive control.  Overall, HPIV-3 induces greater pro-
inflammatory cytokine expression in all three cell types.  Data represent two or 
three independent experiments in the BEAS-2B or Vero and MDBK, respectively.  
Relative quantification (RQ) was determined by first normalizing to GAPDH 
(BEAS-2B and Vero) or RPS9 (MDBK) to give a ΔCt.  ΔΔCt was then determined 
by normalizing to each ΔCt to mock at a given timepoint. Transformation of the 
ΔΔCt (2-ΔΔCt) allowed for representation as a fold change or RQ.  A Dunnett post-
test was conducted in Prism where p<0.05 was considered significant.  An 
asterisk represents a significant fold change over mock at a given timepoint 
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Phylogenetic trees and alignment of conserved protein sequence 
The data in the first two figures confirmed what Nollens et al. [6] 
suggested: TtPIV-1 is more similar to BPIV-3 than to HPIV-3.  However, TtPIV-1 
was originally classified as a novel dolphin PIV based on partial sequence of the 
F and L genes.  Because of the similarities we saw in the viral replication and 
pro-inflammatory cytokine induction profiles, full genome sequencing was 
performed on TtPIV-1 and aligned with multiple strains of both HPIV-3 and BPIV-
3 isolates within the A, B, and C genotype (SF4, Kansas, and SK217; TVMDL15 
and Q5592; 12Q061 and SD0811, respectively).  Sequence alignment was 
performed using ClustalW for each gene individually within the PIV genome: N 
(Fig. 3), phosphoprotein (P) (Fig. 4), matrix (M) (Fig. 5), F (Fig. 6), attachment 
(HN) (Fig. 7), and L (Fig. 8).  In all phylogenetic trees (Fig. 3a-8a), there was 
distinct separation of the HPIV-3 strains from the BPIV-3.  The three genotypes 
of BPIV-3 could be distinguished as well.  TtPIV-1 aligns with the genotype B for 
all genes and was most homologous to the BPIV-3b TVMDL15 isolated from a 
clinical sample of bovine respiratory disease in Texas (GenBank accession 
number KJ647284).  
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Fig. 3  Phylogenetic tree of nucelocapsid (N) gene and alignment of conserved 
protein sequence.   
a The full length N gene of multiple PIV-3 isolates was analyzed for comparison 
to TtPIV-1.  Sequences were aligned using ClustalW.  UPGMA best fit 
phylogenetic trees were produced using MacVector.  b A conserved sequence 
can be seen within the seven and six amino acid segment of the N protein.  The 
N protein was aligned using ClustalW.  Accession numbers for all isolates used 
can be found within the materials and methods section of the paper 
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Fig. 4  Phylogenetic tree of phosphoprotein (P) gene and alignment of conserved 
V protein sequence. The P gene of multiple PIV-3 isolates were analyzed for 
comparison to TtPIV-1.   
a The full length P gene of multiple PIV-3 isolates was analyzed for comparison 
to TtPIV-1.  Sequences were aligned using ClustalW.  UPGMA best fit 
phylogenetic trees were produced using MacVector.  b Insertion of two guanines 
into the P gene create the V protein in paramyxoviruses.  A highly conserved 
cysteine-region serves as a zinc-binding domain.  The V protein was aligned 
using ClustalW.  Accession numbers for all isolates used can be found within the 
materials and methods section of the paper  
 
 
Specific viral proteins were then analyzed for sequence similarity; these 
regions were chosen because previous publications show homology within the 
Paramyxoviridae family.  The polymerase complex consisting of N, P, and L 
proteins were highly conserved.  The N protein of all the strains was 100% 
homologous within two noted areas: a six amino acid sequence (Serine-
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Tyrosine-Alanine-Methionine-Glycine-Valine) and another of seven amino acids 
(Phenylalanine-Alanine-Proline-Glycine-X-Tyrosine-Proline) [21, 22] (Fig. 3b).  
Insertion of two guanines into the P gene creates the V gene, which serves many 
functions for the virus [16].  Within all of the viruses, a highly conserved cysteine-
rich C-terminal domain is seen in the V protein (Fig. 4b).  The N-terminal region 
of the L protein is conserved based on previously published information on the 
Paramyxoviridae family [23] (Fig. 8b).  As seen in Fig. 5b, the C-terminal domain 
of the M protein is also highly conserved [24].   
 
Fig. 5  Phylogenetic tree of matrix (M) gene and alignment of conserved protein 
sequence. The M gene of multiple PIV-3 isolates were analyzed for comparison 
to TtPIV-1.   
a The full length M gene of multiple PIV-3 isolates was analyzed for comparison 
to TtPIV-1.  Sequences were aligned using ClustalW.  UPGMA best fit 
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phylogenetic trees were produced using MacVector.  b A conserved C-terminal 
domain is seen in the M protein.  The M protein was aligned using ClustalW.  
Accession numbers for all isolates used can be found within the materials and 
methods section of the paper 
 
 
 
 
Fig. 6  Phylogenetic tree of fusion (F) gene and alignment of conserved protein 
sequences. The F gene of multiple PIV-3 isolates were analyzed for comparison 
to TtPIV-1.   
a The full length F gene of multiple PIV-3 isolates was analyzed for comparison 
to TtPIV-1.  Sequences were aligned using ClustalW.  UPGMA best fit 
phylogenetic trees were produced using MacVector.   b-d Conserved regions in 
both the F2 b and F1 d domains of the F protein can be seen.  In c, the conserved 
fusion peptide can be seen and the R-X-X-R cleavage site is marked by an 
arrow.  The grey denotes specific amino acid differences between the human 
and bovine isolates.  The F protein was aligned using ClustalW.  Accession 
numbers for all isolates used can be found within the materials and methods 
section of the paper 
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Conserved regions in both the F1 and F2 subunit of the F protein have 
been noted by the same group [25, 26].  In the F2 region a conserved N-terminus 
can be seen in Fig. 6b [26].  The arrow in Fig. 6c shows where the F2 subunit is 
cleaved from the F1 subunit at a conserved R-X-X-R sequence [27].  Moreover, 
the fusion peptide, which is directly involved in viral fusion to the cell membrane, 
consists of an extremely conserved amino terminal domain [28] (Fig. 6c).  
Interestingly, the bovine strains have two distinct amino acid substitutions within 
the fusion peptide: leucine to isoleucine and valine to isoleucine (Fig. 6c, seen in 
light grey).  However, these changes are both conservative as valine, leucine, 
and isoleucine are all non-polar aliphatic amino acids.  The F1 subunit has a 
conserved heptad repeat region that is important for binding to the fusion peptide 
during initial folding [25] (Fig. 6d).  Heptad repeats are also conserved in the HN 
protein of paramyxoviruses [29, 30] (Fig. 7b).  In the conserved region of the HN 
protein there are amino acid substitutions that are specific for the BPIV-3 strains 
(Fig. 7b, seen in light grey).  Isoleucine to leucine is a conservative change, but a 
nonconservative amino acid substitution from threonine to isoleucine could alter 
the three-dimensional structure of the protein.   
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Fig. 7  Phylogenetic tree of attachment (HN) gene and alignment of conserved 
protein sequence. The HN gene of multiple PIV-3 isolates were analyzed for 
comparison to TtPIV-1.   
a The full length HN gene of multiple PIV-3 isolates was analyzed for comparison 
to TtPIV-1.  Sequences were aligned using ClustalW.  UPGMA best fit 
phylogenetic trees were produced using MacVector.   b Within the heptad 
repeats of the HN protein, there is conservation of amino acids.  The grey 
denotes specific amino acid differences between the human and bovine isolates.  
The HN protein was aligned using ClustalW.  Accession numbers for all isolates 
used can be found within the materials and methods section of the paper  
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Fig. 8  Phylogenetic tree of large RNA polymerase (L) gene and alignment of 
conserved protein sequence. The L gene of multiple PIV-3 isolates were 
analyzed for comparison to TtPIV-1.   
a The full length L gene of multiple PIV-3 isolates was analyzed for comparison 
to TtPIV-1.  Sequences were aligned using ClustalW.  UPGMA best fit 
phylogenetic trees were produced using MacVector.  b A conserved amino 
terminal of the L gene is apparent.  The L protein was aligned using ClustalW.  
Accession numbers for all isolates used can be found within the materials and 
methods section of the paper 
 
 
Finally, as summarized in Table 2, TtPIV-1 was found to have >90% 
sequence identity to the bovine PIV-3 genotype B isolates (TVMDL15 and 
Q5592) across all 6 viral genes.  Strikingly, TVMDL15 is 99% identical to TtPIV-1 
in the N, F, and L genes.  These data show that the TtPIV-1 genome is most 
similar to the bovine genotype B strains of PIV-3.   
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Table 2  Percent sequence identity of TtPIV-1 genes compared with those of 
bovine and human PIV-3 isolates 
 
Genotype A viruses: SF4 and Kansas 
Genotype B viruses: TVMDL15 and Q5592  
Genotype C viruses: 12Q061 
 
 
Discussion 
  
These in vitro data show distinct patterns of pro-inflammatory cytokine 
expression based on real-time PCR (Fig. 2) and a differing viral growth pattern 
(Fig. 1) in each of the cell types used during TtPIV-1, BPIV-3, and HPIV-3 
infection.  Full genome sequencing of TtPIV-1 and subsequent phylogenetic 
analysis shows that TtPIV-1 lies within the genotype B of BPIV-3 (Fig. 3a-8a; 
Table 2). 
Similar clinical symptoms are observed during PIV-3 infection in different 
species.  An early clinical sign of BRDC in cattle is loss of appetite, which was a 
commonly reported behavioral abnormality (54%) in dolphins with antibodies to 
PIV [5, 7].  The bottlenose dolphin in which TtPIV-1 was isolated from exhibited 
raspy breaths and cream-colored exudate from the blowhole [6].  This parallels to 
the nasal discharge and coughing seen in humans and cattle with PIV-3 [31, 32].  
Gene Bovine PIV-3 isolates  Human PIV-3 Isolates 
 TVMDL15 
 
Q5592 
 
SF4 Kansas 
 
12Q061 
 
    14702 
 
JS 
 
LZ22 
N 99.0 93.4 86.0 86.2 83.6  78.2 77.8 78.3 
P 98.6 92.3 81.3 81.5 76.9  69.3 69.0 69.6 
M 94.2 90.1 77.7 76.1 76.0  70.3 69.6 70.8 
F 99.1 91.2 79.1 79.2 77.8  72.6 72.8 72.6 
HN 95.7 92.1 81.8 73.8 79.9  65.7 66.0 65.7 
L 99.2 93.7 86.1 86.3 83.4  60.2 58.9 80.2 
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A secondary bacterial infection is commonly associated with PIV-3.  In cattle, this 
is termed BRDC and is an infection with multi-factorial etiology [5].  A study in 
children showed that almost half of the 165 patients positive for PIV were treated 
with antibiotics for a bacterial infection [3].  Specifically, pneumonia was 
observed in 28% of the children positive for PIV-3 [3].  A study which monitored 
the PIV seroconversion in T. truncatus indicated that 3 out of 4 of the animals 
that died within 30 days of seroconversion had a fungal or bacterial coinfection in 
their lungs [7].  Polymicrobial infections are common across species, especially 
the association of PIV with other bacterial or fungal microbes. 
Multiple epithelial cell lines were used to examine possible host 
differences in the three stains of PIV.  PIV-3 naturally infects the bronchial 
epithelium of the human lung, causing lower respiratory infections [9, 31].  BEAS-
2B, a human bronchial epithelial cell line, was chosen for this reason.  A bovine 
bronchial epithelial cell line would have been useful, but no such cell line is 
available.  Therefore, the MDBK cells were used as a bovine host epithelial cell 
line.  Finally, the African green monkey kidney epithelial cell line, Vero cells were 
selected because they are a commonly used mammalian epithelial cell line in 
research.  Vero cells are a classic cell line for virus propagation and isolation, but 
because they do not produce type I interferons using Vero cells for in vitro work 
may not be the best model [33].  However, it is well documented that 
paramyxoviruses can block type I interferon production and downstream 
signaling responses [16, 34-39].  Observed here, the lack of type I interferon 
production may account for the dampened IL-1β and IL-6 pro-inflammatory 
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cytokine response seen in Vero cells as compared with the BEAS-2B and MDBK 
cells.  Fig. 1 demonstrates the importance of using host specific cell lines in that 
the HPIV-3 grew significantly faster in the BEAS-2B while the TtPIV-1 and BPIV-
3 grew significantly more rapidly in the MDBK cells based on the microtiter 
assay.  The HPIV-3 growth does lag behind in the MDBK cells, a bovine 
epithelial cell line and different host than it typically infects, as seen by a 
significantly lower log(titer) in the microtiter plates at 12 hours.  On the contrary, 
the BEAS-2B, a human bronchial epithelial cell line and natural site of infection 
for the HPIV-3, viral growth is more prominent early in infection (12 and 24 
hours).  
In our cytokine expression data (Fig. 2), the HPIV-3 stimulated a potent 
pro-inflammatory profile overall.  Specifically, IL-6 expression in all three cell 
types is upregulated with HPIV-3 infection.  IL-6 has been found to induce an 
antiviral response [40].  A high amount of pro-inflammatory cytokines could also 
be detrimental to viral growth if damage to the cell is occurring.  Signaling via 
both p38-MAPK and NFkB has been shown to contribute to elevated CXCL8 
levels in PIV infection in vitro, which may explain the elevated CXCL8 levels 
across all three viruses we observed here [15, 41].  It has been shown that in 
A549 cells, specifically, HPIV-3 induced high levels of CXCL8 [42].  Statistically 
higher concentrations of CXCL8 were noted in nasal washes from children with 
PIV-3 [3].   
Human and bovine strains of PIV-3 were used to elucidate similarities and 
differences to the recently named TtPIV-1.  The HPIV-3 strain C243 is a lab-
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adapted strain isolated in 1957.  The TtPIV-1 is a clinical strain and published by 
Nollens et al. in 2008 [6].  A vaccine or prototype strain, originally isolated in 
1950, of BPIV-3 was used and is termed SF-4 due to it eliciting “shipping fever” 
in cattle [43-45].  This strain of BPIV-3 is a genotype A North American strain.  
Soon after the TtPIV-1 was characterized, a new BPIV-3 genotype was identified: 
genotype B [46].  The bovine genotype B PIV-3 (BPIV-3b) consists of the 
Australian isolates, of which strain Q5592 is the only fully published sequence of 
BPIV-3b isolates to date.  Genotype C (BPIV-3c) includes isolates from China 
and Korea [47, 48].  BPIV-3 isolates within genotype B and C from the United 
States have recently been fully sequenced (Neill et al., submitted for publication). 
Table 2 depicts the percent sequence identities for TtPIV-1 genes compared to 
the bovine and human PIV-3 isolates.  TtPIV-1 has the highest percent sequence 
identity to the bovine genotype B strains (TVMDL15 and Q5592) for all 6 viral 
genes. 
The novel TtPIV-1 did share significant protein sequence homology with 
the other HPIV-3 and BPIV-3 strains analyzed (Fig. 3b-8b).  It is noteworthy that 
the TtPIV-1 clustered with the BPIV-3 genotype B strains whose reported 
isolation was at a similar time.  The V protein, created from a ribosomal 
frameshift during translation of the P gene, is especially important in suppressing 
type I interferon production [16, 36-38, 49].  The highly conserved cysteine-rich 
region seen in the V protein serves as a zinc-binding domain [16] (Fig. 4b).  We 
observed a conserved cysteine-rich region in the V protein across all of the 
bovine and human PIV-3 isolates analyzed.  Conserved blocks within the fusion 
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protein of paramyxoviurses have been documented [25, 26].  These conserved 
amino acids observed in both F1 and F2 domains are critical for stabilizing the 
prefusion confirmation, folding of the heptad repeats, and oligomerization of the F 
protein [25, 26].  The conserved block in the F1 region (Fig. 6d) has specifically 
been shown to interact with the fusion peptide and these interactions are 
essential for its initial folding [25].  Conserved heptad repeats in the HN protein 
interact with the F protein to aid in membrane fusion [29, 30] (Fig. 7b).  All of the 
bovine strains and TtPIV-1 have two unique amino acid substitutions within HN 
protein (Fig. 7b, seen in light grey).  The nonconservative change from threonine 
to isoleucine could alter the three-dimensional structure of the HN protein enough 
to affect membrane fusion.  Finally, the amino terminal region of the L protein of 
TtPIV-1 is highly conserved within the multiple isolates of PIV-3 [51] (Fig. 8b).  
These authors found that the conserved N-terminal sequence ILYPECHLNSPIV 
is critical for protein function, P binding, and overall transcriptional activity. 
Original nomenclature of a novel TtPIV-1 was based on partial sequence 
information, but the full genome sequence conducted herein shows that the 
TtPIV-1 should be classified with the bovine PIV-3 isolates within genotype B.  
Horwood et al. [46] suggested that the BPIV-3 genotype B strains might have 
crossed from another host species into cattle, thus, creating a novel lineage.  It is 
known that PIV-3 can infect multiple animal species [4].  In fact, there are many 
instances where cross species infections of PIV-3 have been described, 
including BPIV-3 into humans [46, 50].  It is therefore conceivable that TtPIV-1 
may represent a PIV strain that originated in cattle. 
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Abstract 
 
Parainfluenza viruses are known to inhibit type I interferon (IFN) 
production, however there is a lack of information regarding the type III IFN 
response during infection.  Type III IFNs signal through a unique heterodimeric 
receptor, the IFN-λR1/IL-10R2, which is primarily expressed by epithelial cells.  
Parainfluenza virus type 3 (PIV-3) infection is highly restricted to the airway 
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epithelium.  We therefore sought to examine type III IFN signaling pathways 
during PIV-3 infection of epithelial cells.  We used three strains of PIV-3: human 
PIV-3 (HPIV-3), bovine PIV-3 (BPIV-3), and dolphin PIV-1 (TtPIV-1).  Here we 
show that message levels of IL-29 are significantly increased during PIV-3 
infection, yet downstream antiviral signaling molecules are not upregulated to 
levels similar to the positive control.  Furthermore, in Vero cells infected with PIV-
3, stimulation with recombinant IL-29/28A/28B does not cause upregulation of 
downstream antiviral molecules, suggesting that PIV-3 interferes with the 
JAK/STAT pathway downstream of the IFN-λR1/IL-10R2 receptor.  We used 
western blotting to examine the phosphorylation of Stat1 and Stat2 in Vero and 
the bronchial epithelial cell line BEAS-2B.  In Vero cells, we observed reduced 
phosphorylation of the serine 727 (S727) site on Stat1, while in BEAS-2B cells 
Stat1 was dephosphorylated at the tyrosine 701 (Y701) site during PIV-3 
infection.  PIV-3 therefore interferes with the phosphorylation of Stat1 
downstream of the type III IFN receptor.  These data provide new evidence 
regarding strategies employed by parainfluenza viruses to effectively circumvent 
respiratory epithelial cell-specific antiviral immunity. 
 
Importance 
 
Parainfluenza virus (PIV) in humans is associated with bronchiolitis and 
pneumonia and can be especially problematic in infants and the elderly. Also 
seen in cattle, bovine PIV-3 causes respiratory infections in young calves.  In 
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addition, PIV-3 is one of a number of pathogens that contributes to the bovine 
respiratory disease complex (BRDC).  As their name suggests, interferons (IFNs) 
are produced by cells to interfere with viral replication.  Paramyxoviruses have 
previously been shown to block production and downstream signaling of type I 
IFNs.  For the first time, it is shown here that PIV-3 can induce protective type III 
IFNs in epithelial cells, the primary site of PIV-3 infection.  However, we found 
that PIV-3 modulates signaling pathways downstream of the type III IFN receptor 
to block production of several specific molecules that aid in a productive antiviral 
response.  Importantly, this work expands our understanding of how PIV-3 
effectively evades host innate immunity. 
 
Introduction 
 
 Parainfluenza virus 3 (PIV-3) causes a prominent respiratory infection in 
both cattle and humans.  The CDC reports that, in humans, most children have 
antibodies against human PIV-3 (HPIV-3) by 5 years of age 
(http://www.cdc.gov/parainfluenza/hcp/clinical.html).  There is currently no 
vaccine available for control of HPIV-3 infection, however a few studies have 
examined the use of an attenuated bovine PIV-3 (BPIV-3) to protect against 
HPIV-3 because of the homology between bovine and human strains (1-3).  
Given the lack of an efficacious vaccine for HPIV-3, there is a critical need to 
understand the mechanisms of HPIV-3-induced disease and the molecular 
pathways associated with viral modulation of the host antiviral defenses. 
! 68 
Paramyoxviruses are negative sense single stranded RNA viruses which 
are part of the Paramyxoviridae family and Paramyxovirinae subfamily (4).  PIV-3 
is found within the genus Respirovirus.  PIV-3 is a respiratory virus that primarily 
infects the epithelial cells of the lung.  Symptoms of HPIV-3 infection include 
bronchiolitis and pneumonia and HPIV-3 is especially problematic in infants (4).  
Airway epithelial cells recognize viral infection through pattern recognition 
receptors (PRRs): RIG-I like receptors (RLRs) and toll-like receptors (TLRs) (5).  
Viral RNA binds to RLRs and TLRs creating a signaling cascade to produce pro-
inflammatory cytokines and interferons (IFNs).  Type I and III IFNs are important 
in mounting a robust antiviral response by inducing various IFN-stimulating 
genes (ISGs) (6).   
Type I IFNs, particularly IFN-α and -β, are known for their antiviral role; 
however many viruses have been shown to prevent type I IFN production and 
responses.  Paramyxoviruses in particular are known to block type I IFN 
production and downstream signaling pathways (7-16).  A newly described class 
of IFNs, the type III IFNs or IFN-λs, were identified independently and published 
in the same issue of Nature Immunology (17, 18).  The type III IFNs were termed 
IL-29/IL-28A/IL-28B or IFN-λ1/IFN-λ2/IFN-λ3, respectively.  IFN-λs bind a novel 
heterodimeric class II cytokine receptor: IFN-λR1/IL-28Rα and IL-10R2/IL-10Rβ 
(19).  In some infections, including hepatitis C, type I IFNs are used for treatment.  
Nevertheless, giving IFN-α to humans is problematic in itself because of the 
lengthy list of adverse side effects 
(http://www.hepatitis.va.gov/provider/reviews/treatment-side-effects.asp).  IFN-λs 
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may be especially beneficial during respiratory infections because the IFN-λR1 is 
more restricted to epithelial cells (20).  Type III IFNs may therefore be a useful 
treatment in HPIV-3 viral infection until an efficacious vaccine is developed.   
Like type I IFNs, the IFN-λs bind their distinct receptor to induce Janus 
kinase/signal transducers and activators of transcription (JAK/STAT) pathways 
(17,18).  The JAK/STAT pathway activated by either type I or III IFNs can turn on 
many ISGs to control viral infection (6).  The antiviral regulator protein kinase R 
(PKR) is responsible for phosphorylating eukaryotic initiation factor 2α (eIF2α) to 
halt protein synthesis.  OAS (2’-5’ oligoadenylate synthetase) activates RNaseL, 
which, as the name suggests, degrades viral RNA.  The GTPase, MxA 
(myxovirus resistance protein 1), mediates antiviral activity by controlling vesicle 
budding, organogenesis, and cytokinesis (6).  Finally, a multitude of ISGs exist 
as antiviral mediators.  Specifically, ISG56 has been shown to be responsible for 
inhibiting protein synthesis during PIV (21). 
Here we examined type III IFN signaling during a PIV-3 infection.  BEAS-
2B cells, a bronchial epithelial cell line, were used because the epithelial cells of 
the lung are the natural site of infection for PIV-3.  Vero cells were used as a tool 
to study the IFN-λ response independent of IFN-α/β because they are unable to 
produce type I IFNs (22).  Here we demonstrate that IL-29 message is 
upregulated during PIV-3 infection in both Vero and BEAS-2B cells.  Surprisingly 
however, expression of the downstream antiviral molecules PKR, OAS, MxA, and 
ISG56 are not induced to levels near positive control in Vero cells.  This 
suggested that PIV-3 infection may be blocking downstream signaling.  Both the 
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tyrosine 701 (Y701) and serine 727 (S727) phosphorylation site on Stat1 is 
necessary for full activation of downstream antiviral molecules (23-25).  A 
western blot showed that S727 on Stat1 was dephosphorylated in the PIV-3 
infected Vero cells stimulated with type III IFNs, while Y701 was phosphorylated.  
The reverse was true in the BEAS-2B cells: pStat1 S727 was phosphorylated 
normally and Y701 was dephosphorylated during PIV-3 infection.  These results 
suggest that PIV-3 reduces production of antiviral molecules downstream of the 
type III IFN receptor by specifically dephosphorylating Stat1. 
 
Materials and Methods 
 
Cell culture and media recipes   
BEAS-2B cells (ATCC, CRL-9609) were grown as per ATCC’s 
recommendations.  Briefly, flasks were coated in 0.01 mg/mL fibronectin 
(Corning, 356008), 0.03mg/mL bovine collagen type I (Advanced Biomatrix, 
5005-B), and 0.01 mg/mL bovine serum albumin (BSA) (Sigma, A3059).  No 
antibiotics or antimycotics were used in the Bronchial Epithelial Cell Growth 
Medium (BEGM), but BEGM was supplemented with multiple growth factors 
(Lonza, CC-3170).  Vero cells (ATCC, CCL-81) were grown in Eagle’s Minimum 
Essential Medium (EMEM) (ATCC, 30-2003) supplemented with 1x antibiotic-
antimycotic (Sigma, A5955) and 10% heat-inactivated fetal bovine serum (FBS) 
(PAA, A11-265).  Both cells were grown at 37oC in 5% CO2.   
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Viruses 
The Bovine parainfluenza virus 3 strain SF-4 was purchased from ATCC 
(VR-281).  The dolphin isolate of Parainfluenza Virus (TtPIV-1) was obtained 
from the Marine Mammal Health Program at the University of Florida (26).  Both 
BPIV-3 and TtPIV-1 were propagated in primary bovine turbinate (BT) cells.  The 
Human parainfluenza virus 3 C243 strain used was purchased from ATCC (VR-
93).   HPIV-3 was grown in Vero cells.  Eberle et al. concluded that TtPIV-1 is 
actually a BPIV-3 (27).  Therefore, all viruses used throughout this manuscript 
are referred to as PIV-3. 
 
Recombinants and antibodies   
The following recombinant cytokines were purchased from R&D: IL-29 
(1598-IL), IL-28A (1587-IL), IL-28B (5259-IL).  Anti-hIL-29/IFN-λ1 antibody was 
used for blocking experiments (R&D, AF1598). Western blots were performed 
with the following antibodies from Cell Signaling: Stat1 (#9172), Stat2 (#4594), 
phosphor-Stat1 (Ser727) (#9177), phosphor-Stat1 (Tyr701) 58D6 (#9167), 
phosphor-Stat2 (Tyr690) (#4441).  Anti-STAT2 (phosphor Y690) antibody from 
AbCam (ab53132) was used for the BEAS-2B.  β-actin (AbCam, ab82270-50) 
was used as an internal control antibody.  Goat anti-rabbit IgG (H+L), HRP 
conjugate (Thermo, 31460) was used as a secondary antibody for all western 
blots. 
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Time course for real-time PCR   
Virus was added to cells at a multiplicity of infection (MOI) of 2 and left to 
incubate for 6, 12, 24, 48, or 72 hours.  TLR3 agonist, polyinosinic-polycytidylic 
acid (poly I:C) (Sigma, P1530), was used at 20 ug/mL.  A 10 minute 
Lipofectamine 3000 (Invitrogen, L3000-015) treatment with poly I:C was 
necessary in the BEAS-2B to see a positive cytokine response (9).  Recombinant 
treatment of either IFN-α (PBL, #11200-2) and IFN-β (PBL, 11415-1) at 500 
U/mL or IL-29/28A/28B at 1 ug/mL was also used as a positive control.  
Recombinants incubated for 24 hours.  At harvest, samples were collected in 
RLT Lysis Buffer (QIAGEN, 1015762) and 2-beta-mercaptoethanol (2-ME) 
(Sigma, BP176).   
 
RNA extraction and cDNA synthesis   
This technique has been described previous by Eberle et al. (27).  
Samples were collected in RLT Lysis Buffer (QIAGEN, 1015762) and 2-beta-
mercaptoethanol (2-ME) (Sigma, BP176).  Total RNA was isolated using the 
RNeasy MINI RNA Isolation Kit (QIAGEN, 74106) per the manufactures protocol.  
DNase digestion was achieved using the QIAGEN RNase-Free DNase Set 
(79254).  After elution, RNaseOUT (Invitrogen, 10777) was added to each 
sample.  Eluted RNA was transcribed using Random Primers (Invitrogen, 48190) 
and dNTP Mix (Invitrogen, 18427) followed by 5X First-Strand Buffer, 0.1 M DTT, 
and Superscript III Reverse Transcriptase (Invitrogen, 18080) per the 
manufactures instructions.   
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Real-time PCR  
This technique has been described previous by Eberle et al. (27).  Briefly, 
Power SYBR Green PCR Master Mix (Invitrogen, 4367659), 10 µM of both the 
forward and reverse primer (Integrated DNA Technologies), dH2O, and cDNA 
template were combined.  The amplification conditions were: 95oC for 10 
minutes, followed by 40 cycles of 95oC for 15 seconds and 60oC for 1 minute, 
and a final dissociation step.  Plates were run on an Applied Biosystems 7300 
Real-Time PCR System.  Relative gene expression was determined using the 2-
ΔΔCt method (28).  GAPDH was used as a reference gene.  Primers sequences 
used are listed in Table 1.  
 
 
 
TABLE 1  Forward and reverse primer sequences used in real-time PCR assays 
 
 
 
Target Gene Nucleotide Sequence Forward 
Nucleotide Sequence 
Reverse Citation 
    
IL-29 GAA GCC TCA GGT CCC AAT TC GAA GCC TCA GGT CCC AAT TC 42 
IL-28 ACT GCA GCC ACT CCC CTC CAG AAC CTT CAG CGT CAG 42 
IFNa.1 CAG AGT CAC CCA TCT CAG CA CAC CAC CAG GAC CAT CAG TA 32 
IFNa.2 CTG GCA CAA ATG GGA AGA AT CTT GAG CCT TCT GGA ACT GG 32 
IFNb AAG GCC AAG GAG TAC AGT C ATC TTC AGT TTC GGA GGT AA 42 
PKR ACT TTT TCC TGG CTC ATC TC  ACA TGC CTG TAA TCC AGC TA  43 
OAS AGA AGG CAG CTC ACG AAA CC  CCA CCA CCC AAG TTT CCT GTA  44 
MxA (Vero) TTC AGC ACC TGA TGG CCT ATC  TGG ATG ATC AAA GGG ATGTGG  45 
MxA (BEAS-2B) ACC ACA GAG GCT CTC AGC AT  CTC AGC TGG TCC TGG ATC TC  46 
ISG56 CAG CAA CCA TGA GTA CAA AT AAG TGA CAT CTC AAT TGC TC  42 
GAPDH ACT TTG GTA TCG TGG AAG GAC T GTA GAG GCA GGG ATG ATG TTC T 47 
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Recombinant treatment and blocking   
Vero cells pre-incubated with 1 ug/mL of IL-29/IL-28A/IL-28B for 24 hours.  
For the blocking experiments, anti-IL-29 antibody incubated with recombinant IL-
29 for 1 hour at room temperature before being added to the cells for 24 hours.  
After 24 hours with recombinant, virus was added on top of IFN treatment and 
allowed to incubate an additional 24 hours.  At time of harvest, plates were 
placed at -80oC for a single freeze-thaw.  This allows for cell lysis and viral 
release.  Serial dilutions in serum-free EMEM were made of lysates and set on 
Vero cell microtiter plates.  The microtiter plates were read after 6-7 days 37oC in 
5% CO2.  An endpoint titer in units of TCID50/mL was calculated using the Reed-
Muench method (29). 
 
Western blot 
Protein was run on 10% Tris-Glycine Protein Gels (Novex, EC6078BOX) 
followed by transfer to nitrocellulose using iBlot Transfer Stacks (IB3010-02).  
Antibody mixtures were made in 5% BSA, 0.1% Tween-20 in TBS as per the 
recommendation by Cell Signaling for phospho-antibody use.  After blocking for 
30 minutes at room temperature with StartingBlock (TBS) Blocking Buffer 
(Thermo, 37542), antibodies were left to incubate at 4oC with constant shaking 
overnight.  After vigorous washing with 0.1% Tween-20 in TBS, the secondary 
HRP antibody was added for 1 hour at room temperature.  After washing as 
before, the blots were developed with SuperSignal West Dura Chemiluminescent  
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Substrate (Thermo, 34076).  Images were developed using the medical film 
processor SRX-101A by Konica Minolta Medical & Graphic, Inc. 
 
Results 
 
Real-time PCR of type I and type III IFNs in BEAS-2B cells infected with  
PIV-3 
The epithelial cells of the lung are the primary site of PIV-3 infection.  The 
type III IFN response during PIV-3 infection has not been previously described.  
We therefore initially sought to determine if type III IFNs were produced during 
PIV-3 infection in the human bronchial epithelial cell line BEAS-2B.  BEAS-2B 
cells were infected at an MOI of 2 with TtPIV-1 (T), BPIV-3 (B) or HPIV-3 (H), 
and expression of the type III IFNs (IL-28 and IL-29) were measured by real-time 
PCR at multiple time points after infection.  In BEAS-2B cells, IL-29 message 
was induced to levels similar to the positive control, poly I:C, by 24 hours and 
continued through 48 hours (Figure 1).  IL-28 expression was not significantly 
upregulated during PIV-3 infection.  IFN-β expression in the BEAS-2B cells was 
significantly increased during HPIV-3 infection at 24 and 48 hours (Figure 1).  
IFN-α was not significantly upregulated during PIV-3 infection in BEAS-2B cells. 
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FIG 1  Real-time PCR of type I and type III IFNs in BEAS-2B cells infected with 
PIV-3. 
BEAS-2B cells were infected with dolphin (T), bovine (B), or human (H) PIV-3 for 
6, 12, 24, or 48 hours.  Denoted by a (+) sign, treatment of 20 ug/mL Poly I:C 
with 0.6% Lipofectamine 3000 for 10 minutes was used as a positive control.  IL-
28, IL-29, IFNa.1, IFNa.2, and IFNb message levels were measured by real-time 
PCR.  The relative quantification (RQ) was calculated by normalization first to 
GAPDH to give a ΔCt followed by normalizing to mock at a given time point 
(ΔΔCt).  RQ or fold change was then calculated as 2^-ΔΔCt.  A significant change 
from uninfected controls at a particular time point is denoted: *<0.05; #<0.01; 
+<0.001.  
 
 
ELISA of type I and type III IFNs in BEAS-2B cells infected with PIV-3   
ELISA assays were run on cell culture supernatant to confirm our real-time 
PCR results (Figure 2).  BEAS-2B cells produced significant levels of IFN-β 
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protein by 48 and 72 hours post infection with HPIV-3.   Concentrations of IL-29 
protein were also significantly upregulated by 72 hours in response to BPIV-3 
and HPIV-3 infection, but not TtPIV-1. 
 
 
FIG 2  ELISA of type I and type III 
IFNs in BEAS-2B cells infected 
with PIV-3. 
BEAS-2B cells were infected with 
dolphin (T), bovine (B), or human 
(H) PIV-3 for 6, 12, 24, or 48 
hours.  Denoted by a (+) sign, 
treatment of 20 ug/mL Poly I:C with 
0.6% Lipofectamine 3000 for 10 
minutes was used as a positive 
control.  ELISA assays were 
conducted on the supernatants to 
measure human IFN-beta and IL-
29.  Measured in pg/mL, a 
significant change from uninfected 
controls at a particular time point is 
denoted: *<0.05; #<0.01.   
 
 
 
 
Real-time PCR of antiviral molecules downstream of the IFN receptor in 
BEAS-2B cells infected with PIV-3 
PIV-3 infection induced IL-29 production by BEAS-2B cells.  Therefore we 
next wanted to confirm that the expression of downstream antiviral molecules 
was induced as one would expect (Figure 3).  In BEAS-2B cells expression of 
OAS and ISG56 message increased significantly after infection with all of the 
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PIV-3 as early as 24 hours post infection.  However, PKR and MxA message 
levels were not upregulated even by 72 hours post infection.   
 
FIG 3  Real-time PCR of antiviral 
molecules downstream of the IFN 
receptor in BEAS-2B cells infected 
with PIV-3. 
BEAS-2B cells were infected with 
dolphin (T), bovine (B), or human 
(H) PIV-3 for 24, or 48, or 72 
hours.  Denoted by a (+) sign, 
treatment of 20 ug/mL Poly I:C 
with 0.6% Lipofectamine 3000 for 
10 minutes was used as a positive 
control.  Downstream antiviral 
molecules (PKR, OAS, MxA, 
ISG56) levels were measured by 
real-time PCR.  The relative 
quantification (RQ) was calculated 
by normalization first to GAPDH to 
give a ΔCt followed by normalizing 
to mock at a given time point 
(ΔΔCt).  RQ or fold change was 
then calculated as 2^-ΔΔCt.  A 
significant change from uninfected 
controls at a particular time point 
is denoted: *<0.05; #<0.01; 
+<0.001.    
 
 
 
 
Examining type III IFN signaling in BEAS-2B cells using western blot   
Type III IFNs signal through a unique receptor, but are thought to utilize 
the same JAK/STAT signaling pathways as type I IFNs (17, 18).  Failure of the 
BEAS-2B cells to upregulate expression of PKR and MxA in response to PIV 
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infection suggested a blockade in the signaling pathways downstream of the type 
I or type III receptors.  We therefore wanted to determine the effect of PIV 
infection on the JAK/STAT signaling pathway.  BEAS-2B cells were infected with 
TtPIV-1 (T), BPIV-3 (B) or HPIV-3 (H), at an MOI of 2 for 24 hours.  After 24 
hours, the cells were treated with 1 ug/mL of recombinant the IL-29/28A/28B for 
30 minutes.  Western blotting was then used to examine the phosphorylation of 
Stat during PIV-3 infection and subsequent recombinant cytokine treatment.  Stat 
1 has two critical phosphorylation sites: Y701 and S727.  Both are required to 
mediate downstream signaling (23-25).  Representative blots are depicted in 
Figure 4A; densitometry quantification is shown in Figure 4B.  As seen in Figure 
4, phosphorylation at Y701 on Stat1 is significantly reduced during PIV-3 
infection as compared to IFN-λ only treated, while phosphorylation of the S727 
site is unaffected.  Importantly, any calculations normalized to Stat1 were based 
off of the active form, Stat1-α, because Stat1-β lacks the 38-amino-acid 
transcriptional activation domain (30).  Also, during HPIV-3 infection, IFN-λ 
induced phosphorylation at the Y690 site of Stat2 is significantly reduced.  
Phosphorylation of Stat2 Y690 also appears reduced during BPIV-3 and TtPIV-1 
infection, but these changes are not significant. 
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FIG 4  Examining type III IFN signaling in BEAS-2B cells using western blot. 
Vero cells were infected with dolphin (T), bovine (B), or human (H) PIV-3 for 24 
hours.  Twenty-four hours post-infection, Vero cells were stimulated with 
recombinant IL-29/28A/28B (1 ug/mL) for 30 minutes to drive signaling 
downstream of the type III IFN receptor.  (A) A western blot was used to examine 
Stat1 and 2 phosphorylation during PIV-3 infection.  β-actin was used as a 
loading control. (B) Densitometry quantification from western blot in BEAS-2B 
cells was calculated.  Relative quantification from band intensity was calculated 
by normalization to the IFN-λ stimulated positive control.  This RQ was then 
normalized to the appropriate total Stat1 or Stat2 to give a percent pStat1 to total 
Stat1 or pStat2 to total Stat2.  A significant change in phosphorylation from the 
IFN-λ treated positive control is denoted: *<0.05; #<0.01. 
 
 
Because BEAS-2B have the capacity to secrete both type I and type III 
IFNs, it is difficult to dissect the effect of PIV infection on IL-29 signaling, 
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independent of IFN-α/β.  In preliminary experiments, we sought to knockdown 
the expression of the IFNAR1/2 by siRNA treatment.  After siRNA knock down 
and restimulation with recombinant IFN-α/β, there was a 60-70% reduction in 
expression of OAS, MxA, and ISG56 (data not shown).  However, lipofectamine 
treatment alone caused artificial changes in the JAK/STAT signaling pathway 
that would affect any conclusions.  Jensen et al. showed a similar phenomenon 
in that multiple transfection reagents artificially upregulated IFIT1, which is an 
antiviral molecule downstream of IFN receptor (31).   
 
Real-time PCR of type III IFNs in Vero cells infected with PIV-3  
We had observed intriguing results about the type III IFN response in the 
BEAS-2B during PIV-3 infection, however conclusions made in the BEAS-2B 
cells are complicated by the presence of IFN-α/β.  We therefore chose to repeat 
these experiments in a model independent of type I IFN.  Vero cells were 
specifically used because they are not able to produce type I IFNs (22).   As in 
the BEAS-2B, Vero cells were infected at an MOI of 2 with TtPIV-1 (T), BPIV-3 
(B) or HPIV-3 (H), and expression of the type III IFNs (IL-28 and IL-29) were 
measured by real-time PCR at multiple time points after infection.  As observed 
with the BEAS-2B cells, IL-29 message was significantly increased in Vero cells 
by 48 hours post infection in response to all virus strains (Figure 5).  Treatment 
with recombinant IFN-α/β was not able to significantly upregulate IL-29 or IL-28 
message in Vero cells.  IL-28 expression was not detectable in Vero cells during 
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PIV-3 infection; however we were unable to establish a positive control to confirm 
the capacity of these cells to produce IL-28.   
 
FIG 5  Real-time PCR of type 
III IFNs in Vero cells infected 
with PIV-3. 
Vero cells were infected with 
dolphin (T), bovine (B), or 
human (H) PIV-3 for 6, 12, 24, 
or 48 hours.  Recombinant 
IFN-a/b at 500 U/mL 
incubated for 24 hours.  IL-28 
or -29 message levels were 
measured by real-time PCR.  
The relative quantification 
(RQ) was calculated by 
normalization first to GAPDH 
to give a ΔCt followed by 
normalizing to mock at a given 
time point (ΔΔCt).  RQ or fold 
change was then calculated as 2^-ΔΔCt.  A significant change from uninfected 
controls at a particular time point is denoted: *<0.05; #<0.01.    
 
 
Real-time PCR of antiviral molecules downstream of the IFN receptor in 
Vero cells infected with PIV-3 and stimulated with recombinant type III IFNs   
We again wanted to examine downstream antiviral molecules that may be 
upregulated in the BEAS-2B during PIV-3 infection (Figure 6).  Cells were 
infected with TtPIV-1 (T), BPIV-3 (B) or HPIV-3 (H), as in Figure 5, and 
expression of PKR, OAS, MxA, and ISG56 was measured by real-time PCR at 
multiple time points after infection.  As seen in Figure 6, expression of OAS was 
upregulated in response to all three viruses within 48 hours post infection.  ISG56 
expression was also upregulated by 48 hours following HPIV-3 infection and by 
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72 hours following BPIV-3 and TtPIV-1 infection.  However, PKR and MxA 
expression were not significantly induced in response to any of the virus strains.  
Importantly, none of the downstream signaling molecules were expressed at 
levels near that of the recombinant type III or I IFN treatments used as positive 
controls (striped bars), suggesting an effect of PIV-3 on downstream signaling 
pathways.   
 
FIG 6  Real-time PCR of 
antiviral molecules 
downstream of the IFN 
receptor in Vero cells 
infected with PIV-3. 
Vero cells were infected 
with dolphin (T), bovine 
(B), or human (H) PIV-3 
for 24, or 48, or 72 hours.  
Recombinant IFN-a/b 
(500 U/mL) or IL-
29/28A/28B (1 ug/mL) 
incubated for 24 hours.  
Downstream antiviral 
molecules (PKR, OAS, 
MxA, ISG56) levels were 
measured by real-time 
PCR.  The relative 
quantification (RQ) was 
calculated by 
normalization first to 
GAPDH to give a ΔCt 
followed by normalizing 
to mock at a given time 
point (ΔΔCt).  RQ or fold 
change was then 
calculated as 2^-ΔΔCt.  A 
significant change from 
uninfected controls at a 
particular time point is 
denoted: *<0.05; #<0.01; 
+<0.001.    
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We sought to further determine if treatment with recombinant type III IFN 
could overcome the blockade resulting from PIV-3 infection and induce signaling 
downstream of the IFN-λR1/IL-10R2.  Therefore, Vero cells were infected with 
PIV-3 and 24 hours post-infection treated with recombinant type III IFNs for 2 or 
6 hours.  As seen in Figure 7, downstream signaling molecules were still unable 
to be upregulated to levels near that of uninfected, IFN-λ treated positive control 
cells.  Because recombinant type III IFN treatment could not rescue the effect of 
virus infection on downstream antiviral molecules, we hypothesized that PIV-3 
infection directly affects the JAK/STAT signaling pathway that is downstream of 
the IFN-λR1/IL-10R2. 
 
FIG 7  Real-time PCR of antiviral molecules 
downstream of the IFN receptor in Vero 
cells stimulated with recombinant type III 
IFNs after PIV-3 infection. 
Vero cells were infected with dolphin (T), 
bovine (B), or human (H) PIV-3 for 24 
hours.  Twenty-four hours post-infection, 
Vero cells were stimulated with 
recombinant IL-29/28A/28B (1 ug/mL) for 2 
(black bars) or 6 (white bars) hours.  
Downstream antiviral molecules (PKR, 
OAS, MxA, ISG56) levels were measured 
by real-time PCR.  The relative 
quantification (RQ) was calculated by 
normalization first to GAPDH to give a ΔCt 
followed by normalizing to mock at a given 
time point (ΔΔCt).  RQ or fold change was 
then calculated as 2^-ΔΔCt.  A significant 
change from the IFN-λ treated positive 
control at a particular time point is denoted: 
*<0.05; #<0.01; +<0.001. 
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Examining type III IFN signaling in Vero cells using western blot   
IL-29 expression was upregulated in Vero cells infected with PIV-3 (Figure 
5), while downstream antiviral signaling molecules were not induced (Figure 6).  
In addition, recombinant type III IFN treatment of PIV-3 infected Vero cells failed 
to induce expression of downstream antiviral molecules to levels observed in 
uninfected controls (Figure 7).  This suggested that through an unknown 
mechanism, PIV-3 inhibits the JAK/STAT signaling pathway downstream of the 
IFN-λR1/IL-10R2.  Similar to before, Vero cells were infected with TtPIV-1 (T), 
BPIV-3 (B) or HPIV-3 (H), at an MOI of 2 for 24 hours.  After 24 hours, the cells 
were treated with recombinant type III IFN to drive signaling downstream of the 
type III IFN receptor.  In BEAS-2B cells we observed, by western blot, 
dephosphorylation of pStat1 Y701 during PIV-3 infection.  In Figure 8, we show 
that, in Vero cells, dephosphorylation is occurring on the S727 site on Stat1 
during PIV-3 infection.  This dephosphorylation is specific to the S727 site 
because the Y701 site on Stat1 is unaffected.  Depicted by densitometry 
quantitation in Figure 8B, Stat1 phosphorylation at S727 is significantly reduced 
during PIV-3 infection while phosphorylation at the Y701 site significantly 
increased.  In addition, levels of total Stat1 and 2 and phosphorylation at the 
tyrosine 690 site on Stat2 (pStat2 Y690) are not affected.  Again, normalization of 
Stat1 was to Stat1-α (30).   
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FIG 8  Examining type III IFN signaling in Vero cells using western blot. 
Vero cells were infected with dolphin (T), bovine (B), or human (H) PIV-3 for 24 
hours.  Twenty-four hours post-infection, Vero cells were stimulated with 
recombinant IL-29/28A/28B (1 ug/mL) for 30 minutes to drive signaling 
downstream of the type III IFN receptor.  (A) A western blot was used to examine 
Stat1 and 2 phosphorylation during PIV-3 infection.  β-actin was used as a 
loading control.  (B) Densitometry quantification from western blot in Vero cells 
was calculated.  Relative quantification from band intensity was calculated by 
normalization to the IFN-λ stimulated positive control.  This RQ was then 
normalized to the appropriate total Stat1 or Stat2 to give a percent pStat1 to total 
Stat1 or pStat2 to total Stat2.  A significant change in phosphorylation from the 
IFN-λ treated positive control is denoted: *<0.05. 
 
 
 
 
! 87 
Prophylactic treatment of Vero cells with type III IFNs before PIV-3 viral 
infection 
Because PIV-3 blocks signaling downstream of the type III IFN receptor, 
therapeutic treatment with type III IFNs would not be useful.  However, 
prophylactic treatment with IL-29, IL-28A, and/or IL-28B in Vero cells does 
appear effective against PIV-3 infection (Figure 9, left side).  Vero cells were 
treated with the type III IFNs singly or pooled for 24 hours before PIV-3 infection, 
then virus titer was measured 24 hours after PIV-3 infection.  As seen in Figure 
9, recombinant type III IFN treatment resulted in significantly reduced viral titers.  
These results are independent of MOI as an MOI of 2 and 0.2 was used.  This 
antiviral response was specific to the recombinant type III interferon added 
because 80 ug/mL blocking antibody was able to reverse the titer repression 
(Figure 9, right side).   
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FIG 9  Prophylactic treatment of Vero cells with type III IFNs before PIV-3 viral 
infection. 
Vero cells were prophylactically treated with recombinant IL-29/28A/28B alone or 
pooled at 1 ug/mL for 24 hours before TtPIV-1, BPIV-3, or HPIV-3 infection at an 
MOI of 2 or 0.2 for an additional 24 hours.  After the 48 hours, titer plates were 
used to determine the effect of type III IFNs on virus growth. In the right panels, 
IL-29 blocking antibody was added in an increasing dose to show specificity of 
the viral inhibition by type III IFNs.  At the highest blocking antibody dose of 80 
ug/mL, a log(titer) similar to control was observed.  A significant reduction in 
log(titer) as compared to the untreated control sample is denoted: *<0.05; 
#<0.01; +<0.001. 
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Discussion 
 
 Type I and type III IFNs are induced by viral sensors including RLRs 
and TLRs.  IFNs bind their respective receptor to activate JAK/STAT signaling 
and produce downstream antiviral molecules including PKR, OAS, MxA, and 
ISGs.  Parainfluenza virus predominantly infects the airway epithelium.  Because 
the type III IFN receptor is primarily located on epithelial cells we chose to 
examine the IFN-λ response to PIV-3 infection.  While many respiratory viruses 
including RSV, rhinovirus, and influenza have been shown to induce IFN-λs (32-
35), this is the first report, to our knowledge, of PIV-3 virus inducing expression of 
type III IFNs and modulating the downstream antiviral signaling pathways. 
 Here we examined production of type III IFN and antiviral molecules 
downstream of the IFN-λR1/IL-10R2 during PIV-3 infection.  IL-29 message 
levels were significantly increased in BEAS-2B cell as early as 24 hours post 
infection (Figure 1).  Others have shown that type I IFNs are necessary to 
activate type III IFNs, but we did not observe the necessity of IFN-α/β for IL-29 
production in this study (36).  This can be seen in Figure 5, where IL-29 message 
was significantly upregulated by 48 hours post infection with PIV-3 in type I IFN 
deficient Vero cells and recombinant IFN-α/β alone (striped bars) did not 
stimulate IL-29 similar to what was observed during virus infection.  We 
measured protein levels of IL-29 in cell culture supernatant from BEAS-2B cells, 
as shown in Figure 2; multiple IL-29 ELISAs were tested for used with Vero cell 
supernatants, however none were functional.  It is therefore possible that PIV-3 
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could simply inhibit production of type III IFN protein by an unknown mechanism 
in Vero cells and that could in turn prevent induction of downstream antiviral 
molecules.  A significant increase in OAS and ISG56 was seen in BEAS-2B cells 
infected with all three viruses, but this could be due to type I IFNs (Figure 3).  
Furthermore, downstream antiviral molecules, including PKR, OAS, MxA, and 
ISG56, were not upregulated in the Vero cells infected with PIV-3 as compared to 
cells treated with recombinant type I or III (striped bars in Figure 6).  
 There is clear evidence that PIV-3 interferes with signaling 
downstream of the IFN-λR1/IL-10R2 receptor.  Figure 7 showed that Vero cells 
stimulated with recombinant type III IFNs 24 hours post-infection with PIV-3 were 
unable to induce a robust antiviral response.  This was a strong indication that 
PIV-3 interferes with the JAK/STAT signaling pathway downstream of the type III 
IFN receptor.  It is well known that paramyxoviruses block type I IFN production 
(7-16).  A few reports have studied the JAK/STAT downstream signaling 
response during PIV-3 infection, specifically in response to type I IFNs.   
 By examining the phosphorylation downstream of the IFN-λR1/IL-
10R2 through western blots, we specifically observed a decreased 
phosphorylation of pStat1 Y701 in the BEAS-2B (Figure 4) and decrease in 
phosphorylation of the S727 site on Stat1 in the Vero cells (Figure 8) during PIV-
3 infection.  It is well known that both the tyrosine and serine site of Stat 1 are 
necessary for full transcriptional activation (24).  Specifically, phosphorylation at 
the Y701 site has been shown to be vital because of its role in hetero- or homo-
dimerization of Stat1 (24, 30).  On the other hand, the S727 site must be 
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phosphorylated to allow binding of transcriptional coactivators such as CBP/p300 
and MCM5 (24, 25, 37, 38).  Phosphorylation of the serine and tyrosine site on 
Stat1 has been shown to be independent of each other (39); here we observed 
the specific dephosphorylation of S727 or Y701 in the Vero or BEAS-2B cells, 
respectively.  Because the Vero cells are naturally unable to produce type I IFNs, 
it may be most appropriate to base any conclusions off of results obtained in the 
Vero cells.  Other paramyxoviruses have been shown to decrease total Stat1 and 
Stat2 levels to reduce the type I IFN antiviral response (12, 15, 40).  Observed in 
the BEAS-2B (Figure 4), but not seen in the Vero cells (Figure 8), it is important 
to note that total Stat1-α and Stat 2 may be slightly reduced during HPIV-3 
infection.  However, any total Stat1 or 2 reduction was accounted for during 
relative quantification for graphical analysis (Figure 4B and 8B). 
 We hypothesize that PIV-3 induces specific phosphatase activity to 
cause dephosphorylation of Stat1.  The phosphatase SHP-2 has previously been 
shown to dephosphorylate Stat1 at both Y701 and S727 (41).  Future 
experiments will need to be conducted to examine the specific mechanism of 
Stat1 dephosphorylation during PIV-3 infection.   
 Treatment of Vero cells with type III IFNs 24 hours before PIV-3 
infection was able to reduce viral titer (Figure 9).  Type III IFNs are therefore able 
to prophylactically induce downstream antiviral molecules to control viral growth 
in Vero cells.  However, we show for the first time that PIV-3 induces type III IFNs 
and identify a novel mechanism by which PIV-3 inhibits production of 
downstream antiviral molecules PKR, OAS, MxA, and ISG56.  Downstream of 
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the type III IFN receptor, PIV-3 causes reduced phosphorylation of Stat1 to 
negatively affect the JAK/STAT signaling pathway and reduce production of 
antiviral molecules. 
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Abstract 
 
Because viruses enter cells through host membranes and utilize host cell 
machinery for replication, it is known that viruses alter signaling pathways within 
a cell to promote viral entry, replication, and budding.  On the contrary, hosts 
may block signaling pathways desirable to the virus to prevent viral infection.  
Phosphorylation is a key to controlling signaling cascades within a cell.  
Phosphoproteomics uses mass spectrometry to globally detect phosphopeptides 
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in a system.  Using TiO2 phosphopeptide enrichment and LC-MSMS, we 
examined the phosphopeptides in two epithelial cell lines, human BEAS-2B and 
bovine MDBK, following a 5, 15, 30, or 45 minute infection with parainfluenza 
virus 3 (PIV-3).  Several proteins were identified to be uniquely phosphorylated 
following infection with human PIV-3, bovine PIV-3, or dolphin PIV-1.  Of the 
unique proteins identified, some phosphopeptides were detected at multiple time 
points.  The peptide spectral match (PSM) was documented and we observed a 
maximum of four PSMs at any given time point.  We examined six of the uniquely 
phosphorylated proteins further: NACA, eIF3B, NCBP1, SEPT9, UBXN1, and 
TPR.  As protein phosphorylation is the on/off switch to a signaling cascade, any 
change in phosphorylation following viral infection could have a lasting effect on 
viral growth within the cell. 
 
Introduction 
 
Parainfluenza virus 3, PIV-3, is an enveloped, negative sense, single 
stranded RNA virus that is part of the Paramyxovirus family (1).  PIV-3 primarily 
infects epithelial cells of the respiratory tract (2).  Entry of the virus into a cell can 
be accomplished through endocytosis and macropinocytosis, both of which are 
normal cell processes (1).  The PIV-3 genome encodes a RNA-dependent RNA 
polymerase (RdRp), but utilizes host translational machinery to aid in viral 
replication.  Because viruses utilize cellular membranes and machinery to enter, 
replicate, and bud from within a cell, it is therefore expected that a virus would 
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alter signaling pathways within a cell to assist the viral life cycle.  On the contrary, 
the cell may alter signaling pathways to halt cell processes the virus may find 
desirable (3-8).  
Protein phosphorylation is a post-translational modification and a key to 
regulation of signaling events within a cell.  Cellular signaling networks are 
controlled through a cascade of phosphorylation events.  Kinase and 
phosphatase activity on a protein is a dynamic process that can occur rapidly 
within a cell and be transient or long-lived.  It has been shown by others in BHK 
(baby hamster kidney) cells that phosphorylation rose rapidly within the first 
minute after addition of agonist, peaked by 2 minutes, and returned back to basal 
levels by 15-30 minutes post stimulation (9).  Phosphorylation/dephosphorylation 
can occur at multiple, but specific amino acid motif(s) around threonine (Thr/T), 
serine (Ser/S), and/or tyrosine (Tyr/Y) residues of a protein.  Bodenmiller et al. 
note that 30% of all proteins can be phosphorylated at one time within a cell 
(10,11).  
Phosphoproteomics uses mass spectrometry (MS) to analyze the 
phosphorylation of proteins within a system on a large-scale or global level.  
Basic steps of phosphoproteomic approaches include fractionation, protein 
digestion, enrichment of phosphopeptides, and chromatography coupled with MS 
(12).  The distinct difference between proteomics and phosphoproteomics is the 
addition of the enrichment step.  Popular techniques for the enrichment of 
phosphorylated peptides include immobilized metal affinity chromatography 
(IMAC) with iron and metal oxide affinity chromatography (MOAC) with titanium 
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dioxide (TiO2) beads (12).  IMAC was first described by Andersson and Porath in 
1986 for separation of proteins (13), but it was not until 2001 that White and 
coworkers utilized IMAC for the first large-scale phosphoproteomic experiment 
(14,15).  In 2004, TiO2 resin was used for phosphopeptide enrichment by multiple 
groups (16,17).  Both types of affinity chromatography have a higher binding 
capacity for Ser/Thr residues than Tyr, while antibodies for immunoprecipitation 
are more efficient for Tyr residues (18). 
To broaden our understanding of how PIV-3 circumvents the cellular 
signaling machinery critical to the host antiviral response, we used 
phosphoproteomics to look at changes in cellular signaling pathways of the host.  
We examined the global phosphorylation events occurring in human BEAS-2B or 
bovine MDBK cells as early as 5 minutes post-infection with dolphin PIV-1 
(TtPIV-1), bovine PIV-3 (BPIV-3), or human PIV-3 (HPIV-3).  This allowed us to 
examine the early changes in phosphorylation of an epithelial cell that may 
contribute to, or alter, the host response to viral infection. 
 
Materials and Methods 
 
Viruses and cells 
Three strains of parainfluenza virus were used: Human parainfluenza virus 
3 C243 strain (ATCC VR-93), Bovine parainfluenza virus 3 strain SF-4 (ATCC 
VR-281) and dolphin isolate of Parainfluenza Virus (TtPIV-1) (obtained from the 
Marine Mammal Health Program at the University of Florida).  BPIV-3 and TtPIV-
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1 were grown in bovine turbinate (BT) cells, while HPIV-3 was propagated in 
Vero cells.  
BEAS-2B cells were purchased from ATCC (CRL-9609) and grown per 
the manufacturer’s recommendations in Bronchial Epithelial Cell Growth Medium 
(BEGM) (Lonza, CC-3170).  Madin-Darby Bovine Kidney (MDBK-A) (ATCC, 
CCL-81) were grown in Minimum Essential Medium (EMEM) (ATCC, 30-2003) 
supplemented with 1x antibiotic-antimycotic (Sigma, A5955), L-glutamine (Gibco, 
25030), and 10% heat-inactivated fetal bovine serum (FBS) (PAA, A11-265).  
Both cell types were grown at 37oC in 5% CO2.   
 
Virus infection 
Virus was added at a multiplicity of infection (MOI) of 2 onto BEAS-2B or 
MDBK cells for 5, 15, 30, or 45 minutes.  An uninfected control was included per 
time point.  At harvest, ice cold PBS was added to the cells to halt viral entry and 
signaling cascades.  Cells were kept on ice through cell lysis and into the 
acetone precipitation.  
 
Cell lysate and protein quantification 
Probe sonication was used to rapidly lyse pelleted cells.  Cell pellets were 
lysed in Cell Lysis Buffer (BD #559759) with Halt Phosphatase Inhibitor (Thermo 
#78428), sodium orthovanadate (Sigma #S6508), and calyculin A (Cell Signaling 
#9902).  Protein concentration was determined using standard obtained from  
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Pierce (#23209) and the Bio-Rad Protein Assay Dye Reagent Concentrate 
(#500-0006).     
 
Acetone precipitation and trypsin digest 
Protein was isolated by acetone precipitation.  That is, 100ug of protein 
was added to five times the volume of 100% acetone for a minimum of 24 hours 
at -20oC.  The sample was then pelleted at 10,000rpm for 1 hour at 4oC.  After 
resuspension in triethylammonium bicarbonate buffer (TEABB), protein was 
solubilized with 10% sodium deoxycholate acid (Sigma D-6750) and 2% sodium 
dodecyl sulfate (Gibco #15525-025).  This was followed by a reduction with 
50mM tris-(2-carboxyethyl)phosphine (Thermo #20490) and 1M iodoacetimide 
(Sigma I1149).  Mass spectrometry grade Trypsin Gold (Promega #V5280) was 
used to digest the protein into peptides.  The sample was dried in a SpeedVac 
Concentrator (Thermo SC210A) and stored at -20oC until phosphopeptide 
enrichment. 
 
Phosphopeptide enrichment and SDB Clean-up 
Enrichment for phosphopeptides was conducted using the protocol 
provided by GL Sciences, Inc. for the Titansphere Phos-TiO Kit (#5010-21310).  
After enrichment, desalting and clean-up was accomplished using the styrene 
divinylbenzene (SDB) tip from GL Science (#7820-11200).   
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LC-MSMS 
This method was similar to that previously described by Lippolis et al (19).  
Liquid chromatography (LC) used a trapping column (Proxeon Easy-Column, 2 
cm, ID 100 µm, 5 µm, 120A, C18) and an analytical column (Proxeon Easy-
Column, 10 cm, ID 75 µm, 3 µm, 120A, C18).  The LC gradient had a continuous 
flow rate of 300 nl/min under the following conditions: 0% B for 0-3 min; 0-8% B 
from 3-6 min; 8-18% B from 6-86 min; 18-30% B from 86-96 min; 30-90% B from 
96-101 min; 90% B from 101-120 min (A=95% H2O:5% acetonitrile and 0.1% 
formic acid; B=5% H2O:95% acetonitrile and 0.1% formic acid). LC was 
immediately followed by tandem mass spectrometery (MS). The analytical 
column and PicoTip emitter (New Objectives) were attached to a LTQ Orbitrap 
Velos Pro mass spectrometer from Thermo Fisher Scientific using the Proxeon 
Nanospray Flex Ion Source.  Total MS run time was 120 minutes and global data 
dependent method was used.  The MS was set to scan 300-2,000 m/z with a 
resolution of 60,000 FWHM.  CID was used for activation and a minimal signal of 
20,000 was required to trigger MSMS. 
Data was extracted from the LC-MSMS and processed using Discoverer 
version 1.4.1.14.  High confidence peptides were selected based on a False 
Discovery Rate of a decoy database of less than 0.01 or 1%.  The protein 
databases were downloaded from Uniprot.org in October 2013 (human) and 
January 2014 (bovine).  A fragment ion mass tolerance of 1.2 Da and parent ion 
tolerance of 10 ppm were applied.  Carbamidomethylation of cysteine and 
phosphorylation of serine/threonine/tyrosine were specified.  Locations of 
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phosphorylation groups were predicted using phosphoRS 3.0 by Thermo Fisher 
Scientific.   
 
Bioinformatic Analysis 
Phosphopeptides for each viral treatment were compared to uninfected 
samples at each time point.  That is, proteins were identified to be unique if only 
found in the virus treated samples and not in mock.  These unique proteins were 
loaded into Cytoscape and neighboring proteins identified to examine signaling 
networks identified by STRING. 
 
Results 
 
Generation of phosphopeptides for LC-MSMS 
 Figure 1 diagrams the strategy used to isolate samples for LC-MSMS 
(adapted from Dunn et al.)(20).  BEAS-2B or MDBK cells were infected with three 
strains of PIV-3 for 5, 15, 30, or 45 minutes at 37oC.  These short time points 
were selected to examine alterations in epithelial cell signaling early in infection.  
After cell lysis, 100ug of each sample was trypsin digested and enriched for 
phosphopeptides.  Utilization of the TiO2 method resulted in approximately 50-
75% enrichment of phosphopeptides (data not shown).   
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Figure 1.  Flow chart for generation of phosphopeptides for LC-MSMS.  BEAS-
2B or MDBK cells were infected with PIV-3 for 5, 15, 30, or 45 minutes.  After cell 
lysis and tryspin digest, an enrichment step was preformed to isolate 
phosphopeptides from the samples.  The basic steps during TiO2 enrichment are 
shown on the right side.  Briefly, peptides were loaded onto a column of TiO2 
resin.  Phosphopeptides have high affinity for the TiO2 column and stayed bound 
to the column, while non-phosphopeptides flowed through.  After washing, 
phosphopeptides were eluted and collected for analysis on the LTQ Orbitrap MS. 
Phosphorylation events upon PIV-3 infection 
 
LC-MSMS allowed us to examine the total phosphopeptides in the virus 
infected or uninfected samples.  In further analysis we identified peptides seen 
only in virus infected samples and not in mock at each time point.  The Venn 
diagrams in Figure 2 reveals the total number (pooled time points) of unique or 
overlapping phosphopeptides identified by LC-MSMS in PIV-3 infected and 
uninfected samples in BEAS-2B (left) and MDBK (right) cells.  As seen in Figure 
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2, there were 172, 171, and 173 uniquely phosphorylated peptides detected by 
LC-MSMS in BEAS-2B cells following HPIV-3, BPIV-3, or TtPIV-1 infection, 
respectively.  Overall, more phosphopeptides were observed in MDBK cells than 
BEAS-2B.  
 
Figure 2.  Venn 
diagram illustrating 
the number of unique 
or overlapping 
phosphopeptides 
identified by LC-
MSMS.  Shown here 
are the number of 
unique or shared 
phosphorylated 
peptides recorded by 
LC-MSMS in PIV-3 
infected versus 
uninfected samples 
in BEAS-2B (left) or 
MDBK (right) cells 
over all four time 
points.   
 
 
 
Effects on signaling pathways upon PIV-3 infection in BEAS-2B cells 
We used Cytoscape to examine specific signaling pathways altered during 
early PIV-3 infection.  In Cytoscape, we were able to overlay unique peptides 
seen in virus infection through all four time points with peptides from mock 
infected samples.  From this we identified a list of peptides that were uniquely 
phosphorylated across all time points during PIV-3 infection and not seen in 
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uninfected cells (Table 1).  Table 1 also includes the number of peptide spectrum 
matches (PSM) per protein and the time point(s) each phosphorylated protein 
was observed; proteins are arranged by highest PSM and earliest time point 
starting at the top of each virus section to the lowest PSM/latest time point at the 
bottom.  The highest PSM number observed for a protein at a single time point 
was four peptides.  Six phosphorylated peptides were detected at more than one 
time point post infection with HPIV-3 and not observed in mock: ZMYND8, 
SEPT9, TPR, DDC54, ABCF1, and TMX1.  Following BPIV-3, two 
phosphorylated peptides were observed at all four time points post infection: 
PROSER2 and SEPT9.  Finally, four phosphorylated peptides were detected by 
LC-MSMS at multiple time points post infection with TtPIV-1:  SEPT9, MRC2, 
CCDC86, and TMX1.  SEPT9, TPR, TMX1, and RAD23B were the only 
overlapping proteins identified in all three virus infections, while CCDC86 and 
GABBR2 were the only two proteins similar between BPIV-3 and TtPIV-1 
infection.  TMX1 and SEPT9 were both seen in multiple time points in all three 
viruses.  
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Table 1.  Uniquely identified phosphoproteins 5, 15, 30, and 45 minutes post HPIV-3, BPIV-3, and TtPIV-1 infection 
in BEAS-2B cells. 
  Protein Name Gene Name 
Uniprot 
ID Biological Process 
5 
min 
15 
min 
30 
min 
45 
min 
HPIV-3 Protein(kinase(C-binding(protein(1( ZMYND8 Q9ULU4 Transcription cofactor; ubiquitin-protein ligase 4 3   
Septin-9(( SEPT9 Q9UHD8 Small GTPase; cytoskeletal protein  2 1 2 
Nucleoprotein(TPR( TPR P12270 Nuclear import/export 2 1   
ATP-dependent(RNA(helicase(DDX54( DDX54 Q8TDD1 RNA helicase 2  2  
ATP-binding(cassette(sub-family(F(member(1( ABCF1 Q8NE71 
ATP-binding cassette (ABC) 
transporter; translation elongation 
factor; hydrolase 
 2  2 
Thioredoxin-related(transmembrane(protein(1( TMX1 Q9H3N1 Disulfide oxidoreductase activity   2 2 
Ubiquitin-regulatory-X((UBX)-domain-
containing(protein(1( UBXN1 Q04323 ATPase binding; ubiquitin binding  4   
Nuclear(distribution(protein(nudE-like(1( NDEL1 Q9GZM8 Microtubule binding    4 
Eukaryotic(translation(initiation(factor(3(
subunit(B( EIF3B P55884 Translation initiation factor  3   
Opioid(growth(factor(receptor(( OGFR Q9NZT2 Receptor  2   
Niban-like(protein(1(( FAM129B Q96TA1 Negative regulator of apoptotic process  2   
Nascent(polypeptide-associated(complex(
subunit(alpha( NACA Q13765 
DNA binding; transcription coactivator 
activity    2 
UV(excision(repair(protein(RAD23(homolog(B RAD23B P54727 Damaged DNA-binding protein    2 
Opioid-binding(protein/cell(adhesion(molecule( OPCML Q14982 Receptor    2 
Single-minded(homolog(2(( SIM2 Q14190 Basic helix-loop-helix transcription factor; nucleic acid binding 1    
Guanine(nucleotide-binding(protein(G(s)(
subunit(alpha(isoforms(XLas GNAS Q5JWF2 GTPase activity; signal transducer 1    
Alpha-1B-glycoprotein( A1BG P04217 Membrane-bound signaling molecule; immunoglobulin receptor superfamily 1    
Nuclear(cap-binding(protein(subunit(1( NCBP1 Q09161 mRNA splicing factor  1   
Sphingosine(kinase(2( SPHK2 Q9NRA0 Carbohydrate kinase  1   
E3(ubiquitin-protein(ligase(TRIM11( TRIM11 Q96F44 Ubiquitin-protein ligase  1   
!
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Table 1 continued 
 
 Protein Name( Gene Name 
Uniprot 
ID Biological Process 
5 
min 
15 
min 
30 
min 
45 
min 
HPIV-3 RelA-associated(inhibitor PPP1R13L Q8WUF5 Transcription corepressor  1   
Proline-rich(AKT1(substrate(1( AKT1S1 Q96B36 Neutrophin TRK receptor signaling pathway; signaling pathway receptor  1   
Transcription(factor(E2F7 E2F7 Q96AV8 Transcription factor; nucleic acid binding   1  
Cordon-bleu(protein-like(1 COBLL1 Q53SF7 Actin filament network binding   1  
Zinc(finger(Ran-binding(domain-containing(
protein(2(( ZRANB2 O95218 RNA binding; transcription factor    1 
Disintegrin(and(metalloproteinase(domain-
containing(protein(22 ADAM22 Q9P0K1 Zinc ion binding; integrin binding    1 
Tyrosine-protein(kinase(ZAP-70( ZAP70 P43403 Non-receptor tyrosine protein kinase    1 
VWFA(and(cache(domain-containing(protein(1 CACHD1 Q5VU97 Calcium ion transport    1 
ADP-ribosylation(factor(4 ARF4 P18085 Small GTPase    1 
Endothelial(transcription(factor(GATA-2( GATA2 P23769 Zinc finger transcription factor; nuclease    1 
Fragile(X(mental(retardation(syndrome-related(
protein(1( FXR1 P51114 RNA binding protein    1 
Sodium(bicarbonate(cotransporter(3( SLC4A7 Q9Y6M7 Cation transporter    1 
 
BPIV-3 Proline and serine-rich protein 2 PROSER2 Q86WR7 ORF, Unknown function 2 2 2 2 
Septin-9( SEPT9 Q9UHD8 Small GTPase; cytoskeletal protein 1 2 1 1 
Thioredoxin-related(transmembrane(protein(1( TMX1 Q9H3N1 Disulfide oxidoreductase activity  2  3 
Sodium(bicarbonate(cotransporter(3( SLC4A7 Q9Y6M7 Cation transporter   1 2 
Eukaryotic(translation(initiation(factor(3(
subunit(B( EIF3B P55884 Translation initiation factor 4    
ATP-binding(cassette(sub-family(F(member(1( ABCF1 Q8NE71 
ATP-binding cassette (ABC) 
transporter; translation elongation 
factor; hydrolase 
   4 
Nucleoprotein(TPR TPR P12270 Nuclear import/export 3    
Coiled-coil(domain-containing(protein(86( CCDC86 Q9H6F5 RNA binding 3    
UV(excision(repair(protein(RAD23(homolog(B( RAD23B P54727 Damaged DNA-binding protein  3   
Protein(NDRG1( NDRG1 Q92597 Tumor suppressor; protein binding  3   
Protein(FAM122A FAM122A Q96E09 Unknown function 2    
!
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Table 1 continued !
 
 Protein Name Gene Name 
Uniprot 
ID Biological Process 
5 
min 
15 
min 
30 
min 
45 
min 
BPIV-3 PDZ(and(LIM(domain(protein(7( PDLIM7 Q9NR12 Transcription factor; non-motor actin binding protein  2   
Tumor(suppressor(p53-binding(protein(1( TP53BP1 Q12888 DNA binding  2   
Gamma-aminobutyric(acid(type(B(receptor(
subunit(2 GABBR2 O75899 G-protein coupled receptor  2   
Nuclear(pore(complex(protein(Nup98-Nup96( NUP98 P52948 Transporter  2   
Bifunctional(glutamate/proline--tRNA(ligase EPRS P07814 Ligase    2 
Protein(Shroom3( SHROOM3 Q8TF72 Ligand-gated ion channel; non-motor actin binding protein    2 
Glutamine--fructose-6-phosphate(
aminotransferase([isomerizing](1( GFPT1 Q06210 Transaminase    2 
Cytoplasmic(protein(NCK1(( NCK1 P16333 Receptor binding; adapter protein 1    
WW(domain-containing(transcription(regulator(
protein(1( WWTR1 Q9GZV5 Transcriptional coactivator 1    
WD(repeat-containing(protein(44( WDR44 Q5JSH3 Colocalize with RAB11 in vesicle recycling 1    
Protein(PML( PML P29590 DNA binding; SUMO binding 1    
Protein(PTHB1( BBS9 Q3SYG4 Protein transport; cilium assembly 1    
Centrosome-associated(protein(350( CEP350 Q5VT06 Microtubule binding & anchoring 1    
Lysyl(oxidase(homolog(1( LOXL1 Q08397 Oxidoreductase 1    
Carbonic(anhydrase(12(( CA12 O43570 Dehydratase  1   
Histone-lysine(N-methyltransferase(2A KMT2A Q03164 Methyltransferase; DNA binding protein  1   
DENN(domain-containing(protein(4C DENND4C Q5VZ89 Protein transport; guanine-nucleotide exchange factor  1   
Heat(shock(protein(beta-1( HSPB1 P04792 RNA binding; protein kinase binding  1   
RelA-associated(inhibitor(( PPP1R13L Q8WUF5 Transcription corepressor  1   
Connector(enhancer(of(kinase(suppressor(of(
ras(3 CNKSR3 Q6P9H4 
Sodium ion transport; Negative 
regulator ERK   1  
Dynamin-1( DNM1 Q05193 Receptor; serine protease; oxidase    1 
60S(acidic(ribosomal(protein(P2( RPLP2 P05387 Ribosomal protein    1 
Very-long-chain(3-oxoacyl-CoA(reductase( HSD17B12 Q53GQ0 Dehydrogenase; reductase    1 
!
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Table 1 continued !
 Protein Name( Gene Name 
Uniprot 
ID Biological Process 
5 
min 
15 
min 
30 
min 
45 
min 
BPIV-3 Zinc(finger(Ran-binding(domain-containing(
protein(2( ZRANB2 O95218 RNA binding; transcription factor    1 
Metalloreductase(STEAP3( STEAP3 Q658P3 Oxidoreductase    1 
Serine/threonine-protein(phosphatase(4(
regulatory(subunit(3A( SMEK1 Q6IN85 Regulatory subunit    1 
 
TtPIV-1 Septin-9  SEPT9 Q9UHD8 Small GTPase; cytoskeletal protein 1 1  2 
C-type mannose receptor 2 MRC2 Q9UBG0 Receptor 2 1   
Coiled-coil domain-containing protein 86  CCDC86 Q9H6F5 RNA binding 1  2  
Thioredoxin-related transmembrane 
protein 1  TMX1 Q9H3N1 Disulfide oxidoreductase activity 1  1  
Nucleoprotein TPR  TPR P12270 Nuclear import/export 3    
UV excision repair protein RAD23 homolog 
B  RAD23B P54727 Damaged DNA-binding protein 3    
Large proline-rich protein BAG6  BAG6 P46379 Enzyme modulator 2    
Importin subunit alpha-1  KPNA2 P52292 Transfer/carrier protein 2    
Protein FAM178A FAM178A Q8IX21 Unknown function 2    
Protein kinase C-binding protein 1  ZMYND8 Q9ULU4 Transcription cofactor; ubiquitin-protein ligase  2   
Nebulette  NEBL O76041 Actin filament binding  2   
Proline and serine-rich protein 2 PROSER2 Q86WR7 ORF, Unknown function   2  
Calmodulin-binding transcription activator 1 CAMTA1 Q9Y6Y1 Transcription factor   2  
Nuclear cap-binding protein subunit 1  NCBP1 Q09161 mRNA splicing factor 1    
Mitochondrial antiviral-signaling protein  MAVS Q7Z434 CARD domain binding; protein kinase 1    
PDZ and LIM domain protein 3 PDLIM3 Q53GG5 Transcription factor; non-motor actin binding protein 1    
Gamma-aminobutyric acid type B receptor 
subunit 2  GABBR2 O75899 G-protein coupled receptor 1    
Astrocytic phosphoprotein PEA-15  PEA15 Q15121 
MAPK activation; transport; 
neutrophin TRK receptor signaling 
pathway 
1    
Junctional adhesion molecule B  JAM2 P57087 Receptor 1    
Niban-like protein 1 FAM129B Q96TA1 Negative regulator of apoptotic process 1    
!
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Table 1 continued !
 Protein Name Gene Name 
Uniprot 
ID Biological Process 
5 
min 
15 
min 
30 
min 
45 
min 
TtPIV-1 Metaxin-1 MTX1 Q13505 Protein transport 1    
Ribosome-binding protein 1  RRBP1 Q9P2E9 RNA binding; ribosome receptor 1    
Zinc finger Ran-binding domain-containing 
protein 2  ZRANB2 O95218 RNA binding; splice factor 1    
Vascular endothelial growth factor B  VEGFB P49765 Growth factor 1    
Xin actin-binding repeat-containing protein 
1  XIRP1 Q702N8 Actin family cytoskeletal protein 1    
Mediator of RNA polymerase II 
transcription subunit 24  MED24 O75448 Transcriptional coactivator 1    
Protein SOX-15  SOX15 O60248 HMG box transcription factor; nucleic acid binding 1    
ATP-dependent RNA helicase DDX54  DDX54 Q8TDD1 RNA helicase 1    
Transmembrane protein 100 TMEM100 Q9NV29 Developmental protein 1    
Mitochondrial import inner membrane 
translocase subunit TIM16  PAM16 Q9Y3D7 Translocation; protein transport  1   
Iporin  RUSC2 Q8N2Y8 Rab GTPase binding  1   
SLAIN motif-containing protein 2 SLAIN2 Q9P270 (+) end of growing microtubules  1   
Ubiquitin-associated protein 2  UBAP2 Q5T6F2 RNA binding   1  
Roundabout homolog 3  ROBO3 Q96MS0 Neuronal migration; developmental protein   1  
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2  ATP2A2 P16615 Transport; ATP binding   1  
CST complex subunit CTC1  CTC1 Q2NKJ3 DNA binding   1  
Carbamoyl-phosphate synthase 
[ammonia], mitochondrial  CPS1 P31327 Transferase; ligase   1  
Heterogeneous nuclear ribonucleoprotein 
D-like HNRNPDL O14979 DNA binding; RNA binding   1  
Queuine tRNA-ribosyltransferase subunit 
QTRTD1  QTRTD1 Q9H974 Zinc ion binding; transferase   1  
Geranylgeranyl transferase type-2 subunit 
beta RABGGTB P53611 Acyltransferase   1  
Lysine-specific demethylase 2A  KDM2A Q9Y2K7 Histone demethylase; DNA binding   1  
Peripherin  PRPH P41219 Structural protein intermediate filament   1  
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From the list in Table 1 we then considered “first neighbors.”  These are 
neighboring proteins that have previously been shown to have a direct 
association with the protein of interest through such methods as 
coimmunoprecipitation, His-tag, anti-baiting, tandem affinity, molecular sieving, 
and cross-linking studies.  Therefore, these neighbors are most likely involved in 
a signaling cascade with the uniquely identified protein.  Because PIV-3 
replicates almost exclusively in airway epithelial cells, we focused on the 
examination of HPIV-3 infection in BEAS-2B cells.  Signaling cascade pathways 
altered during HPIV-3 infection in BEAS-2B included, but were not limited to, 
changes in mitogen-activated protein kinase (MAPK), microtubule, interferon, 
and ubiquitin pathways. 
Six unique proteins of interest were examined further and seen in yellow in 
Figures 3-7: NACA, eIF3B, NCBP1, SEPT9, UBXN1, and TPR.  These six 
proteins were chosen because multiple PSMs were detected, the peptide was 
observed at multiple time points, and/or it was seen in more than one virus 
infection.  “Neighbors” are colored red in the signaling webs in all figures.  The 
nascent polypeptide-associated subunit NACA was phosphorylated at S166 by 
45 minutes post-infection with HPIV-3 (Figure 3).  Phosphorylation of eukaryotic 
translation initiation factor, eIF3B, at the S83 site was seen after 5 minutes of 
BPIV-3 and 15 minutes of HPIV-3 infection.  A first neighbor of eIF3B, subunit 1 
of the nuclear cap-binding protein (NCBP1, also known as cap binding protein 
80/CBP80) was also phosphorylated in TtPIV-1 infection after 5 minutes and 15 
minutes following HPIV-3 infection (Figure 4).  NCBP1 was phosphorylated at the 
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S22 site.  Here we saw that Septin-9 (SEPT9) was phosphorylated at S30 in 
multiple time points: 15, 30 and 45 minutes post HPIV-3 infection; 5, 15, 30, and 
45 minutes post infection with BPIV-3; 5, 15, and 45 minutes after TtPIV-1 
infection (Figure 5).  The T207 site of the ubiquitin regulatory domain, UBXN1, 
was phosphorylated 15 minutes post infection with HPIV-3 (Figure 6).  Finally, 
phosphorylation of the S2155 site on the nucleoprotein TPR was seen in all three 
viruses 5 minutes post-infection and persisted in HPIV-3 infection through 15 
minutes (Figure 7).  As seen in Figure 7, the TPR “first neighbor” network 
connects to other unique proteins phosphorylated during infection including SIM2 
and TCOF1. 
 
Figure 3.  Bioinformatic 
analysis to map a signaling 
pathway of NACA and 
neighboring proteins.  NACA is 
shown in yellow, while red 
shows the first neighbors.  
These first neighbors are 
proteins that have been shown 
to have some association with 
the NACA, the protein of 
interest.  This therefore shows 
what signaling molecules may 
be affected by changes in 
phosphorylation of NACA. 
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Figure 4.  Bioinformatic analysis to map a signaling pathway of eIF3B, NCBP1, 
and neighboring proteins.  Proteins eIF3B and NCBP1 are shown in yellow, while 
red shows the first neighbors. These first neighbors are proteins that have been 
shown to have some association with the NACA, the protein of interest.  This 
therefore shows what signaling molecules may be affected by changes in 
phosphorylation of NACA.  Interestingly, eIF3B and NCBP1 are both proteins of 
interest and first neighbors.   
 
Figure 5.  Bioinformatic analysis to map a 
signaling pathway of SEPT9 and 
neighboring proteins.  SEPT9 is shown in 
yellow, while red shows the first neighbors.  
These first neighbors are proteins that 
have been shown to have some 
association with the SEPT9, the protein of 
interest.  This therefore shows what 
signaling molecules may be affected by 
changes in phosphorylation of SEPT9. 
 
 
Effects on signaling pathways upon PIV-3 infection in MDBK cells 
In the MDBK cells, noted differences were observed in the six unique 
proteins of interest: NACA, eIF3B, NCBP1, SEPT9, UBXN1, and TPR.  Similar to 
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in the BEAS-2B, NACA was phosphorylated at the S166 site in MDBK cells 5, 15, 
and 30 minutes post TtPIV-1 Infection, 5 and 15 minutes post BPIV-3 infection, 
and 15 minutes post HPIV-3 infection.  It is to note that in the mock at 15 minutes 
NACA was phosphorylated at the S166 site as well.  Though eIF3B was not seen 
in the MDBK cells, other initiation factors (eIF3C and eIF3G) were noted.  
However, phosphorylation of eIF3 was phosphorylated in both mock and PIV-3 
infected samples.  Furthermore, in the MDBK cells NCBP1 was phosphorylated 
in multiple samples at the S22 site, this was the phosphorylation site observed in 
BEAS-2B as well.  At both 5 and 45 minutes post infection, the mock and all 
three virus treated samples were phosphorylated at S22.  Interestingly though, 
phosphorylation of the S22 site of NCBP1 was not observed in mock samples 15 
and 30 minutes post infection, but was phosphorylated at 15 minutes post BPIV-
3 and HPIV-3 infection and 30 minutes after infection with all three viruses.  In 
the MDBK cells, TPR was phosphorylated at S2152 but this is a homologous site 
to what was observed in the BEAS-2B.  Multiple samples, including uninfected 
controls, were phosphorylated at S2152 on TPR: 5 minutes post TtPIV-1 and 
BPIV-3 infection and mock; in all samples including mock 15 and 30 minutes post 
infection; 45 minutes post all virus infected samples but not mock.  Finally, no 
sites of phosphorylation were observed for SEPT9 and UBXN1 in the MDBK 
cells.  Phosphorylation of Septin-2 (SEPT2) was detected in both mock and all 
virus infected samples in MDBK cells. 
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Figure 6.  Bioinformatic analysis to map a signaling pathway of UBXN1 and 
neighboring proteins.  UBXN1 is shown in yellow, while red shows the first 
neighbors.  These first neighbors are proteins that have been shown to have 
some association with the UBXN1, the protein of interest.  This therefore shows 
what signaling molecules may be affected by changes in phosphorylation of 
UBXN1. 
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Figure 7.  Bioinformatic 
analysis to map a 
signaling pathway of 
TPR and neighboring 
proteins.  TPR is shown 
in yellow, while red 
shows the first 
neighbors.  These first 
neighbors are proteins 
that have been shown 
to have some 
association with the 
TPR, the protein of 
interest.  This therefore 
shows what signaling 
molecules may be 
affected by changes in 
phosphorylation of TPR.  
It is of note that TCOF1 
and SIM2 are uniquely 
phosphorylated proteins 
identified and also first 
neighbors to TPR. 
 
 
Discussion 
 
Because parainfluenza virus entry involves host cell membranes and 
viruses hijack cellular machinery for replication, it is well accepted that specific 
signaling pathways within a cell are altered during viral infections.  
Phosphorylation is central to controlling signaling cascades within a cell.  Kinase 
and phosphatase activity is rapid to quickly turn on/off signaling pathways.  Here 
we specifically wanted to examine alterations in the signaling cascades as early 
as 5 minutes post PIV-3 infection in the bovine and human cell lines MDBK and 
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BEAS-2B, respectively.  To date, specific pathways are known to be modified 
during paramyxovirus infection; we used phosphoproteomics to look at 
phosphorylation of proteins on a global scale to elucidate new pathways PIV may 
alter.   
We focused on proteins that were phosphorylated during initial PIV-3 virus 
infection, but not seen in uninfected BEAS-2B cells.  A list of these proteins can 
be seen in Table 1 for all three viruses.  Interestingly, though dolphin PIV-1 was 
previously shown to be a bovine PIV-3 by Eberle et al., only two proteins were 
similar between the BPIV-3 and TtPIV-1 infection: CCDC86 and GABBR2 (21).  
However, TtPIV-1 is a genotype B BPIV-3, while the SF-4 strain of BPIV-3 used 
herein is a genotype A strain.  We further examined six unique proteins (yellow) 
phosphorylated during HPIV-3 infection and their “neighbors” (red) shown in 
Figures 3-7: NACA, eIF3B, NCBP1, SEPT9, UBXN1, and TPR. 
NACA was phosphorylated at S166; though the S53 and T159 sites are 
catalytic kinases, coordinated phosphorylation of nearby sites may be necessary 
for activation/inactivation of the pathway (RegPhos 2.0).  Fitting for its name, 
nascent polypeptide-associated complex, NACA is one of the first cytosolic 
proteins to contact nascent polypeptides emerging from the ribosome (22,23).  A 
first neighbor to NACA, VCAM1 (Vascular Cell Adhesion Molecule 1) is inducible 
in BEAS-2B cells and has a known role in recruitment of intraepithelial 
lymphocytes and eosinophils into the airway during infection (24-26). 
Of the eukaryotic translation initiation factors, eIF3B is a major scaffolding 
subunit (27).  An alteration in phosphorylation of eIF3B is not surprising because 
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PIV-3 replicates by using host translational machinery.  Also a first neighbor to 
NACA, VCAM1 was seen as a first neighbor to eIF3B.  A uniquely 
phosphorylated protein (yellow) and first neighbor of eIF3B, NCBP1 was 
phosphorylated at the S22 site, which has been described to be phosphorylated 
by the ribosomal protein S6 kinase, 70kDa polypeptide 1 (RPS6KB1) (28,29).   
Septin-9 (SEPT9) was detected at multiple time points following infection 
with all three viruses.  In all cases, the S30 site on SEPT9 was phosphorylated; 
phosphorylation of the S30 site has been documented by others (30).  The septin 
family can interact with a number of other cellular components: actin, 
microtubules, phospholipid membranes, and other septins (31).  In addition to 
their role in cytokinesis, septins are involved in several other biological processes 
in non-dividing cells; septin rings form a diffusion barrier at the base of cilium and 
can act as a scaffold to restrain membrane-bound proteins such as receptors and 
transporters (31).  Intriguingly, septins have been shown to aid in viral replication 
and have an antiviral role.  Septin-6 not only interacts with a nonstructural protein 
of hepatitis C virus, but when septin-6 was knocked out there was reduced viral 
replication (32).  On the contrary, other members of the septin family were shown 
to have an antiviral role during vaccinia virus infection, that is, siRNA treatment of 
septin-11 actually enhanced viral replication (33).  This antiviral effect of septin 
observed by Beard et al., may be explained by a “cage” effect similar to what has 
been observed with the Shigella flexneri where septins actually cage off or entrap 
the bacteria to prevent spread of infection (33,34).  The use of septins in bacterial  
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endocytosis has been studied to some degree, but the specific role of SEPT9 
during PIV-3 infection has yet to be elucidated (35,36).     
UBXN1, also known as stress-activated kinase (SAPK1) substrate protein 
1, is an ubiquitin binding protein.  Wang et al. showed that UBXN1 disrupts the 
MAVS/TRAF3/TRAF6 signalosome to negatively regulate antiviral type I 
interferon signaling (37).  As a negative regulator of host antiviral response, 
depletion of UBXN1 through RNAi induced production of IFN-β and 
proinflammatory cytokines to enhance the antiviral response (37).  Wang et al. 
conclude that UBXN1 specifically acts as a dominant-negative binder to MAVS 
by blocking the TRAF3/6 binding sites critical for MAVS-mediated IFN induction 
(37,38). 
Classically, TPR is a nucleoprotein and associated with the nuclear basket 
as part of the nuclear pore complex and nuclear import pathway.  Here we saw 
that the S2155 (S2152 in bovine) was phosphorylated.  This specific site is 
phosphorylated by the substrate ERK1/2, a member of the MAPK pathway (39).  
In addition, MAP3K4 (Mitogen Activated Protein Kinase Kinase Kinase 4) is seen 
as a first neighbor of TPR.  Other first neighbors of TPR included the TLR signal 
adaptor TRAF6, cell adhesion molecule VCAM1, cell cycle division protein 
CDC37, histone deacetylase HDAC9, and the signal transducer SMAD2.  
However, in contrast to the large 267 kDa TPR protein, in the BEAS-2B we 
observed a 55 kDa protein by western blot with anti-TPR antibodies (data not 
shown).  This 55 kDa protein is most likely a rearranged form of TPR in BEAS-2B 
cells that occurs naturally. That is, chromosomal rearrangement has occurred 
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where the TPR and NTRK1 genes form tropomyosin-related kinase (TRK-T1 or 
TRK-T2) (40).  This rearrangement is not surprising because the BEAS-2B are a 
cell line transformed by an adenovirus 12-SV40 virus hybrid.  Interestingly, TRK 
has been shown to be involved in clathrin-mediated endocytosis which could 
relate to the change in phosphorylation of the TPR/TRK protein we observed 
here during PIV-3 entry (41).  Furthermore, autophosphorylation of TRK can 
create docking sites for other adaptor proteins involved in PI3K, MAPK, and 
PLCγ signaling pathways (42).  Interestingly, after infection with HPIV-3 and 
TtPIV-1, uniquely identified phosphorylation sites on AKT1S1 and PEA15, 
respectively, were detected and are involved in the NTRK receptor pathway. 
 
Conclusions 
 
As observed by phosphoproteomics, extensive changes in signaling 
pathways were seen as early as 5 minutes post PIV-3 infection.  Differences 
were observed in phosphorylation between the bovine MDBK and human BEAS-
2B epithelial cell lines, but importantly some of the same phosphorylation sites 
were noted between the two upon PIV-3 infection.  For future experiments, it 
would be interesting to suppress/activate different signaling pathways and 
examine the effect on viral replication and growth.   Here we observed 
phosphorylation modifications in MAPK, microtubule, interferon, and ubiquitin 
pathways, to name a few.  These changes in phosphorylation during initial viral 
entry can have a profound effect on the viral life cycle as a whole.   
123 !
Acknowledgements 
 
Funding for this project was supported in part by the Office of Naval 
Research grant N0001412IP20029.  We would also like to thank Usha Muppirala 
and Andrew Severin with the Genome Informatics Facility at Iowa State 
University for assistance with analysis.   
 
References 
 
 
(1) Chang, A.; Dutch, R. E. Paramyxovirus Fusion and Entry: Multiple Paths 
to a Common End. Viruses. 2012, 4, 613–636. 
 
(2)   Henrickson, K. J. Parainfluenza viruses. Clin. Microbiol. Rev. 2003, 16,  
242–264. 
 
(3) Diehl, N.; Schaal, H. Make Yourself at Home: Viral Hijacking of the 
PI3K/Akt Signaling Pathway. Viruses 2013, 5, 3192–3212. 
 
(4) Fields, A. P.; Bednarik, D. P.; Hess, A.; May, W. S. Human  
immunodeficiency virus induces phosphorylation of its cell surface  
receptor. Nature 1988, 333, 278–280. 
 
(5) Keating, J. A.; Striker, R. Phosphorylation events during viral  
infections provide potential therapeutic targets. Rev. Med. Virol. 2011, 22,  
166–181. 
 
(6) Moraz, M.-L.; Pythoud, C.; Turk, R.; Rothenberger, S.; Pasquato, A.;  
Campbell, K. P.; Kunz, S. Cell entry of Lassa virus induces tyrosine  
phosphorylation of dystroglycan. Cell. Mirobiol. 2012, 15, 689–700. 
 
(7) Qie, L.; Marcellino, D.; Herold, B. C. Herpes simplex virus entry is  
associated with tyrosine phosphorylation of cellular proteins. Virology  
1999, 256, 220–227. 
 
(8) Urata, S.; Ngo, N.; la Torre, de, J. C. The PI3K/Akt Pathway  
Contributes to Arenavirus Budding. J. Virol. 2012, 86, 4578–4585. 
 
 
124 !
(9)  Alaluf, S.; Mulvihill, E. R.; McIlhinney, R. A. Rapid agonist mediated 
phosphorylation of the metabotropic glutamate receptor 1 alpha by protein kinase 
C in permanently transfected BHK cells. FEBS letters. 1995, 367, 301–305. 
 
(10) Bodenmiller, B.; Malmstrom, J.; Gerrits, B.; Campbell, D.; Lam, H.; 
Schmidt, A.; Rinner, O.; Mueller, L. N.; Shannon, P. T.; Pedrioli, P. G.; et al. 
PhosphoPep–a phosphoproteome resource for systems biology research in 
Drosophila Kc167 cells. Mol. Syst. Biol. 2007, 3, 139. 
 
(11) la Fuente van Bentem, de, S.; Mentzen, W. I.; la Fuente, de, A.; Hirt, H. 
Towards functional phosphoproteomics by mapping differential phosphorylation 
events in signaling networks. Proteomics 2008, 8, 4453–4465. 
 
(12) Roux, P. P.; Thibault, P. The coming of age of phosphoproteomics--from 
large data sets to inference of protein functions. Mol. Cell. Proteomics 2013, 12, 
3453–3464. 
 
(13) Andersson, L.; Porath, J. Isolation of phosphoproteins by immobilized 
metal (Fe3+) affinity chromatography. Anal. Biochem. 1986, 154, 250–254. 
 
(14) Ficarro, S. B.; McCleland, M. L.; Stukenberg, P. T.; Burke, D. J.; Ross, M. 
M.; Shabanowitz, J.; Hunt, D. F.; White, F. M. Phosphoproteome analysis by 
mass spectrometry and its application to Saccharomyces cerevisiae. Nat. 
Biotechnol. 2002, 20, 301–305. 
 
(15) Macek, B.; Mann, M.; Olsen, J. V. Global and site-specific quantitative 
phosphoproteomics: principles and applications. Annu. Rev. Pharmacol. Toxicol. 
2009, 49, 199–221. 
 
(16) Engholm-Keller, K.; Larsen, M. R. Technologies and challenges in large-
scale phosphoproteomics. Proteomics 2013, 13, 910–931. 
 
(17) Montoya, A.; Beltran, L.; Casado, P.; Rodríguez-Prados, J.C.; Cutillas, P. 
R. Characterization of a TiO2 enrichment method for label-free quantitative 
phosphoproteomics. Methods 2011, 54, 370–378. 
 
(18) López, E.; Wang, X.; Madero, L.; López-Pascual, J.; Latterich, M. 
Functional phosphoproteomic mass spectrometry-based approaches. Clin. 
Transl. Med. 2012, 1, 20. 
 
(19) Lippolis, J. D.; Brunelle, B. W.; Reinhardt, T. A.; Sacco, R. E.; Nonnecke, 
B. J.; Dogan, B.; Simpson, K.; Schukken, Y. H. J. Proteomics 2014, 108, 373–
381. 
 
125 !
(20) Dunn, J. D.; Reid, G. E.; Bruening, M. L. Techniques for phosphopeptide 
enrichment prior to analysis by mass spectrometry. Mass Spectrom. Rev. 2010, 
29, 29–54. 
(21)    Eberle, K. C.; Neill, J. D.; Venn-Watson, S. K.; McGill, J. L.; Sacco, R. E. 
Novel Atlantic bottlenose dolphin parainfluenza virus TtPIV-1 clusters with bovine 
PIV-3 genotype B strains. Virus Genes. 2015, 51, 198–208. 
 
(22)   Beatrix, B.; Sakai, H.; Wiedmann, M. The alpha and beta subunit of the 
nascent polypeptide-associated complex have distinct functions. J. Biol. Chem. 
2000, 275, 37838–37845. 
 
(23)   Wang, S.; Sakai, H.; Wiedmann, M. NAC covers ribosome-associated 
nascent chains thereby forming a protective environment for regions of nascent 
chains just emerging from the peptidyl transferase center. J. Cell Biol. 1995, 130, 
519-–528. 
 
(24) Atsuta, J.; Sterbinsky, S. A.; Plitt, J.; Schwiebert, L. M.; Bochner, B. S.;  
Schleimer, R. P. Phenotyping and cytokine regulation of the BEAS-2B human 
bronchial epithelial cell: demonstration of inducible expression of the adhesion 
molecules VCAM-1 and ICAM-1. Amer. J. Respir. Cell Mol. Biol. 1997, 17, 571– 
582. 
 
(25) Papi, A.; Johnston, S. L. Respiratory epithelial cell expression of vascular 
cell adhesion molecule-1 and its up-regulation by rhinovirus infection via NF-κB  
and GATA transcription factors. J. Biol. Chem. 1999, 274, 30041–30051. 
 
(26) Wang, S. Z.; Hallsworth, P. G.; Dowling, K. D.; Alpers, J. H.; Bowden, J. J.;  
Forsyth, K. D. Adhesion molecule expression on epithelial cells infected with  
respiratory syncytial virus. Euro. Respir. J. 2000, 15, 358–366. 
 
(27) Liang, H.; Ding, X.; Zhou, C.; Zhang, Y.; Xu, M.; Zhang, C.; Xu, L. 
Knockdown of eukaryotic translation initiation factors 3B (EIF3B) inhibits 
proliferation and promotes apoptosis in glioblastoma cells. Neurol. Sci. 2012, 33, 
1057–1062. 
 
(28) Wilson, K. F. Cdc42 Stimulates RNA Splicing via the S6 Kinase and a 
Novel S6 Kinase Target, the Nuclear Cap-binding Complex. J. Biol. Chem. 2000, 
275, 37307–37310. 
 
(29) Wu, X.; Renuse, S.; Sahasrabuddhe, N. A.; Zahari, M. S.; Chaerkady, R.; 
Kim, M.S.; Nirujogi, R. S.; Mohseni, M.; Kumar, P.; Raju, R.; et al. Activation of 
diverse signalling pathways by oncogenic PIK3CA mutations. Nat. Comm. 2014, 
5, 4961. 
 
 
 
126 !
(30)    Schmutz, C.; Ahrné, E.; Kasper, C. A.; Tschon, T.; Sorg, I.; Dreier, R. F.;  
Schmidt, A.; Arrieumerlou, C. Systems-level overview of host protein  
phosphorylation during Shigella flexneri infection revealed by  
phosphoproteomics. Mol. Cell. Proteomics. 2013, 12, 2952–2968. 
 
(31)      Mostowy, S.; Cossart, P. Septins: the fourth component of the  
cytoskeleton. Nat. Rev. Mol. Cell Biol. 2012, 13, 183–194. 
 
(32)    Kim, C. S.; Seol, S. K.; Song, O. K.; Park, J. H.; Jang, S. K. An RNA- 
Binding Protein, hnRNP A1, and a Scaffold Protein, Septin 6, Facilitate Hepatitis 
C Virus Replication. J. Virol. 2007, 81, 3852–3865. 
 
(33)    Beard, P. M.; Griffiths, S. J.; Gonzalez, O.; Haga, I. R.; Pechenick  
Jowers, T.; Reynolds, D. K.; Wildenhain, J.; Tekotte, H.; Auer, M.; Tyers, M.; et  
al. A Loss of Function Analysis of Host Factors Influencing Vaccinia virus  
Replication by RNA Interference. PLoS ONE. 2014, 9, e98431. 
 
(34)    Mostowy, S.; Bonazzi, M.; Hamon, M. A.; Tham, T. N.; Mallet, A.; Lelek, 
M.; Gouin, E.; Demangel, C.; Brosch, R.; Zimmer, C.; et al. Entrapment of  
Intracytosolic Bacteria by Septin Cage-like Structures. Cell Host Microbe. 2010,  
8, 433–444. 
 
(35)    Mostowy, S.; Nam Tham, T.; Danckaert, A.; Guadagnini, S.; Boisson  
Dupuis, S.; Pizarro-Cerdá, J.; Cossart, P. Septins Regulate Bacterial Entry into 
Host Cells. PLoS ONE. 2009, 4, e4196. 
 
(36)    Phan, Q. T.; Eng, D. K.; Mostowy, S.; Park, H.; Cossart, P.; Filler, S. G. 
Role of Endothelial Cell Septin 7 in the Endocytosis of Candida albicans. mBio 
2013, 4, e00542–13. 
 
(37) Wang, P.; Yang, L.; Cheng, G.; Yang, G.; Xu, Z.; You, F.; Sun, Q.; Lin, 
R.; Fikrig, E.; Sutton, R. E. UBXN1 Interferes with Rig-I-like Receptor-Mediated 
Antiviral Immune Response by Targeting MAVS. Cell Rep. 2013, 3, 1057–1070. 
 
(38)   Paz, S.; Vilasco, M.; Arguello, M.; Sun, Q.; Lacoste, J.; Nguyen, T. L. A.; 
Zhao, T.; Shestakova, E. A.; Zaari, S.; Bibeau-Poirier, A.; et al. Ubiquitin 
regulated recruitment of IκB kinase ε to the MAVS interferon signaling adapter. 
Mol. Cell. Biol. 2009, 29, 3401–3412. 
 
(39)  Parker, R.; Vella, L. J.; Xavier, D.; Amirkhani, A.; Parker, J.; Cebon, J.;  
Molloy, M. P. Phosphoproteomic Analysis of Cell-Based Resistance to BRAF  
Inhibitor Therapy in Melanoma. Front. Oncol. 2015, 5, 95. 
 
 
 
127 !
(40) Greco, A.; Miranda, C.; Pagliardini, S.; Fusetti, L.; Bongarzone, I.; Pierotti, 
M. A. Chromosome 1 rearrangements involving the genes TPR and NTRK1 
produce structurally different thyroid-specific TRK oncogenes. Genes 
Chromosomes Cancer 1997, 19, 112–123. 
 
(41) Zheng, J.; Shen, W. H.; Lu, T. J.; Zhou, Y.; Chen, Q. Clathrin-dependent 
endocytosis is required for TrkB-dependent Akt-mediated neuronal protection 
and dendritic growth. J. Biol. Chem. 2008, 283, 13280–13288. 
 
(42) Huang, E. J.; Reichardt, L. F. TRK receptors: roles in neuronal signal 
transduction. Annu. Rev. Biochem. 2003, 72, 609–642. 
 
 128 
CHAPTER 5: GENERAL CONCLUSIONS AND FUTURE DIRECTION 
 
Development of a safe and effective vaccine against parainfluenza virus 3 
(PIV-3) is key to controlling this respiratory virus that has a profound effect on 
human health, especially infants and the elderly.  Efforts to develop a PIV-3 
vaccine have focused on a variety of strategies: cold passage, reverse genetics, 
host range attenuation, and chimeric vaccines (Sato and Wright, 2008).  
Successive passage at lower temperatures through classic attenuation strategies 
was used to develop the most advanced PIV-3 vaccine.  In 2004, the attenuated 
vaccine strain PIV3-cp45, named for its 45 cold passages, was safe and 
immunogenic in infants 6-18 months of age as observed by a phase 2 clinical 
trial (Belshe et al., 2004).  Because of the success with PIV3-cp45, a reverse 
genetics approach has allowed for development of a recombinant PIV3-cp45 
(rcp45) that has a short passage history to minimize possible contamination 
(Karron et al., 2011).  Another promising method to develop a HPIV-3 vaccine 
has been to use attenuated bovine PIV-3 (BPIV-3) strains either alone or as a 
chimeric backbone replaced with the HPIV-3 fusion and hemmagglutinin-
neuraminidase genes (Greenberg et al., 2005; Haller et al., 2000; Karron et al., 
1995; Karron et al., 2012).  To aid in the development of an efficacious vaccine 
we must first understand the differences between PIV-3 strains and how these 
viruses behave on a molecular level.  This dissertation touches the surface of 
both of these aims.   
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First in Chapter 2, we conducted full genome sequencing on a recently 
isolated dolphin PIV virus, TtPIV-1.  Original nomenclature of TtPIV-1 by Nollens 
et al. was based on partial sequence of the fusion and RNA polymerase genes, 
however based on full sequence analysis here we showed that TtPIV-1 is in fact 
a BPIV-3 genotype B isolate.  The genotype B isolates are newer described 
strains of BPIV-3 and found in North America.  The reported isolation of 
TVMDL15, a BPIV-3b strains analyzed herein, and TtPIV-1 were off the Gulf 
Coast of the United Stated at approximately the same time.  Symptoms similar to 
those observed in infants with HPIV-3 are seen in calves with BPIV-3 infection 
including nasal discharge and coughing (Dinter and Morein, 1990; Henrickson et 
al., 2003;).  Additionally, because the use of BPIV-3 in human PIV-3 vaccines is 
being explored, it is important to continue to characterize newly isolated strains of 
BPIV-3. 
Furthermore, it is necessary to further our understanding of PIV-3 viral 
infection on a molecular level, including how the virus induces or blocks signaling 
responses inside of an infected cell.  In Chapter 3, we examined the type III 
interferon (IFN) response during PIV-3 infection of BEAS-2B and Vero cells.  
These cells were chosen because epithelial cells of the lung are the primary site 
of PIV-3 infection.  We showed that though message levels of type III IFNs are 
upregulated in both BEAS-2B and Vero cells, downstream antiviral signaling 
molecules were not increased as expected.  We further examined the JAK/STAT 
signaling pathway downstream of the type III IFN receptor.  By western blot, we 
observed a decrease in phosphorylation of S727 or Y701 site on Stat1 in Vero or 
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BEAS-2B, respectively.  We concluded that PIV-3 reduced phosphorylation of 
Stat1 to block a productive antiviral response from occurring.  PP1 has a 
multifunctional role during infections and has been shown to interact with MDA5 
and RIG-I pathways early in IFN signaling (Wies et al., 2013).  More specifically, 
the phosphatase SHP-2 has already been shown to dephosphorylate Stat1 at 
both Y701 and S727 (Wu et al., 2002).  Further experiments would need to be 
conducted to examine the specific mechanism behind blocked phosphorylation or 
dephosphorylation of Stat1 during PIV-3 infection.  Finally, when Vero cells were 
prophylactically treated with type III IFNs 24 hours before infection, we observed 
a decrease in PIV-3 titer.  Therefore, if a vaccine is able to circumvent the 
blockade of downstream antiviral molecules by PIV-3, the vaccine may be more 
effective.  Before a vaccine is developed, a small molecule to block the 
desphosphorylation of Stat1 or prophylactic type III IFNs could also be an 
effective treatment for high-risk infants and elderly patients. 
We continued to examine the signaling pathways affected during PIV-3 
infection, this time on a global scale.  In Chapter 4, we use a phosphoproteomic 
approach to look at changes in phosphorylation at 5, 15, 30, and 45 minutes after 
PIV-3 infection in human BEAS-2B and bovine MDBK cells.  These short time 
points were chosen because the changes in cell signaling upon initial infection 
can have a long-term affect on the viral life cycle.  Here we did observe changes 
in phosphorylation early in PIV-3 infection.  Further studies, including western 
blotting, need to be conducted to confirm the phosphorylation events we 
observed through phosphoproteomics.  Changes in protein phosphorylation can 
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in turn alter signaling pathways and have a profound effect on viral infectivity; this 
includes pathways relating to cell microtubules for viral entry or translation for 
viral propagation.  It would be interesting in future experiments to artificially 
control phosphorylation of any of the pathways we observed here to see the 
effect on PIV-3 infection in vitro. 
The studies herein aid in our understanding of new PIV-3 isolates.  In 
addition, we examined, for the first time, specific type III interferon signaling 
pathways associated with PIV-3 infection to help comprehend the infection on a 
molecular level.  The type III IFN signaling response can specifically be useful in 
development of a successful treatment for PIV-3 in humans.  A chimeric PIV-3 
vaccine or adjuvant that is able to induce type I and III IFNs may provide a more 
protective immune response to PIV-3 because of induction of downstream 
antiviral molecules. 
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Abstract 
 
Chronic inflammation has been associated with insulin resistance and type 
2 diabetes (T2D) in humans.  Postmortem hepatic and splenic tissue from a 46-
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year-old geriatric male bottlenose dolphin (Tursiops truncatus) with insulin 
resistance (chronic hyperinsulinemia with hyperglycemia), chronic inflammation 
(white blood cell count greater than 12,000 cells/µL), and mild fatty liver disease 
was evaluated for elevated pro-inflammatory mediators.  Cytokine mRNA 
expression in postmortem hepatic and splenic tissue, as determined by real-time 
PCR, included an array of cytokines: TGF-β, TNF-α, IFN-γ, IL-2, IL-4, IL-10, IL-
12p40, IL-13, and IL-18.  Values from this dolphin were compared to a younger 
reference dolphin with no known chronic metabolic perturbations or inflammation.  
Levels of TGF-β, TNF-α, and IL-4 were higher in the case dolphin's liver 
compared to that of the reference dolphin.  In the case dolphin's spleen, IL-10 
and IFN-γ mRNA was upregulated while IL-4 was less than reference dolphin.  
IL-18 and IL-13 were upregulated in both tissues.  Fluorescent 
immunohistochemistry (IHC) utilized the following antibodies: anti-porcine IL-6, 
anti-bovine IFN-γ, IL-4, and IL-10, anti-human TGF-β, anti-ovine IL-1β, and anti-
dolphin IL-8.  Fluorescent IHC in spleen from the case dolphin revealed staining 
of IL-4, IL-6, IL-8, and TGF-β throughout the tissue.  IL-10 and IFN-γ were seen 
to predominate in areas surrounding the follicles of splenic tissue.  This is the first 
characterization of cytokine levels in dolphin hepatic and splenic tissue.  While 
there are limitations to a case study, this report of inflammatory biomarkers in 
tissues of a dolphin with insulin resistance and fatty liver disease are similar to 
those observed in human patients. 
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Introduction 
 
Chronic inflammation is associated with, and can be a driver of, insulin 
resistance and type 2 diabetes (T2D) in humans (Corkey, 2011; Dandona et al., 
2004; Fernandez-Real and Ricart, 2003; Festa et al., 2000 and 2002; Yudkin et 
al., 1999).  Primary cytokines involved in insulin resistance-associated 
inflammation are tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) 
(Abbatecola et al., 2004; Kern et al., 2001; Pradhan et al., 2001; Xu et al., 2003).  
Additional cytokines associated with metabolic perturbations include IL-1β, IL-8, 
IL-10, transforming growth factor-beta (TGF-β), and nerve growth factor (Eckel et 
al., 2005).  Neutralization of TNF-α in obese-diabetic rodents lead to elevated 
insulin-stimulated peripheral glucose uptake and an overall increase in insulin 
sensitivity in adipocytes as compared to the controls (Hotamisligil et al., 1993; 
Hotamisligil et al., 1994a; Hotamisligil et al., 1994b).  TNF-α signaling induces 
production of suppressor of cytokine signaling (SOCS), I kappa B kinase beta 
(Ikkβ), C-jun N-terminal kinase 1 (JNK1), and nitric oxide, which block insulin 
receptor substrate signal transduction of the insulin receptor (de Luca and 
Olefsky, 2008).  While obesity is a commonly researched underlying factor 
related to chronic inflammation and insulin resistance in humans, inflammation 
can also be an independent predictor of insulin resistance in non-obese people 
(Taniguchi et al., 2002). 
Bottlenose dolphins (Tursiops truncatus) are emerging as a model for T2D 
(Venn-Watson et al., 2011a).  After dolphins consume a high-protein diet, plasma 
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glucose levels rise for up to 5 hours, and oral administration of dextrose causes a 
sustained period (up to 10 hours) of hyperglycemia.  Further, dolphins are 
susceptible to diseases and conditions associated with insulin resistance, 
including chronic inflammation (Venn-Watson et al., 2011b).  Dolphin-specific 
cytokine assays were developed to evaluate cytokine activity in this species.  The 
current case study applied real-time polymerase chain reaction (PCR) assays 
and fluorescent immunohistochemical (IHC) staining in postmortem hepatic and 
splenic tissue from a geriatric, 46-year-old dolphin with a history insulin 
resistance (chronic hyperinsulinemia with hyperglycemia), chronic inflammation, 
and fatty liver disease.  In humans, hyperinsulinemia and chronic inflammation 
have been correlated with insulin resistance (Corkey, 2011; Trayhurn and Wood, 
2004).  Specifically, middle-aged males and females with metabolic syndrome 
have an increased risk for T2D (Wilson et al., 2005).  This dolphin died from 
anaphylactic shock, and related immunologic changes were also expected.  
Immune values from the case dolphin were compared to those from a reference 
dolphin with no metabolic perturbations.  The presence and quantity of cytokines 
in the spleen and liver were determined using real-time PCR assays and 
fluorescent IHC for mRNA and protein, respectively.  This study represents first 
evaluation of cytokines in bottlenose dolphin hepatic and splenic tissue. 
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Materials and Methods 
 
Subjects and sample collection 
Fresh postmortem tissue from liver and spleen were collected 
opportunistically from two bottlenose dolphins in the same managed population.  
Spleen was selected as a representative secondary lymphoid tissue.  Samples 
were snap frozen and stored in liquid nitrogen.  The case dolphin was a geriatric 
46-year-old male with insulin resistance (chronic glucose greater than 144 mg/dL 
and 2h postprandial insulin greater than 20 µIU/mL) that died unexpectedly from 
anaphylactic shock.  The reference dolphin was a juvenile male with no evidence 
of liver disease that died acutely from non-infectious and non-toxic causes.  This 
dolphin had no history of elevated liver enzymes or iron, and no significant 
findings in hepatic, splenic, or pancreatic tissue upon histologic examination.  
Historical medical records, including blood data and histologic reports, from the 
case animal were also reviewed. 
 
Total RNA extraction and cDNA synthesis 
Tissues were removed from RNAlater Solution (Qiagen) and minced 
before adding TRIzol Reagent (Invitrogen).  Phase separation was accomplished 
by addition of chloroform and the samples centrifuged at 3400rpm for 1 hour at 
4oC.  The supernatant was collected and isopropyl alcohol added to precipitate 
the RNA.  After centrifugation at 3400rpm for 30 minutes at 4oC, the supernatant 
was discarded and the RNA pellet was washed with 75% ethanol and 
centrifuged.  The supernatant was discarded and the RNA pellet allowed to dry 
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before being dissolved in RNase-free water.  DNase digestion was accomplished 
using the Ambion TURBO DNA-free kit.  RNaseOUT (Invitrogen) was added to 
each sample.  First-strand cDNA synthesis was successful with 300 ng of RNA 
transcribed using Random Primers and dNTP Mix followed by 5X First-Strand 
Buffer, 0.1 M DTT, and Superscript III Reverse Transcriptase (Invitrogen).   
 
Real-time PCR assay   
PCR primers were developed specifically for SYBR Green quantification.  
All sequences were based on previously published information (Sitt et al., 2008).  
Briefly, SYBR Green Mastermix (Invitrogen) was added to 10 µM of both the 
forward and reverse primer (Integrated DNA Technologies), dH2O, and cDNA 
template.  The amplification conditions were: 95oC for 10 minutes, followed by 40 
cycles of 95oC for 15 seconds and 60oC for 1 minute, and a final dissociation 
step.  Plates were run on an Applied Biosystems 7300 Real-Time PCR System.  
Relative gene expression was determined using the 2-ΔΔCt method (Livak and 
Schmittgen, 2011).  S-9 was used as the reference gene. 
 
Fluorescent IHC 
Snap-frozen sections of dolphin spleen in optimal cutting temperature 
compound (OCT) (Tissue Tek) were cut, 5 microns thick, with a cryostat and 
placed on clean poly-L-lysine coated glass slides.  The tissue was immediately 
fixed with an equal ratio of acetone to methanol for 10 minutes.  A liquid-wax 
boundary was drawn around the tissue with a Super PAP Pen (Invitrogen) to 
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protect against reagent loss.  Tissues were blocked with Background Buster 
(Accurate Chemical and Scientific Corporation) and avidin, if applicable, from an 
Avidin/Biotin Blocking Kit (Vector) for 45 minutes.  Following a wash with 1X Tris 
buffer, primary cytokine antibodies were added at varying concentrations and 
incubated at room temperature for 1 hour, unless noted (Table 1).  After washing 
with 1X Tris buffer, appropriate secondary antibodies conjugated to either Alexa 
Fluor 488 or Alexa Fluor 594 (Invitrogen) were then incubated at a concentration 
of 5 µg/mL for another hour at room temperature in the dark.  Ki67 antibody 
(Thermo Scientific) was used at a 1:500 dilution and incubated for one hour with 
both primary and secondary antibody as described above.  In some cases, CD2 
was costained as described previously at a concentration of 1:100.  The slides 
were washed a final time with 1X Tris buffer and allowed to dry.  Sections were 
mounted using VECTASHIELD HardSet Mounting Medium with DAPI (Vector) 
and coverslipped.  The mounting medium was left to dry and staining to cure 
overnight until visualization the following day using a Zeiss Axio Scope.A1  
microscope. 
 
 
Table 1 | Primary antibodies used for fluorescent IHC 
Cytokine 
specificity 
Type of 
antibody Species Dilution Source 
     
CD2 mAb (IgG1) dolphin 1:100 UC Davis UC-F21.C 
Ki67 pAb multiple species 1:500 Thermo Scientific PA5-19462 
IL-1β pAb ovine 1:50 overnight Serotec AHP 423 
IL-4 mAb (IgG2a) bovine 1:25 Serotec MCA2371 
IL-6 pAb porcine 1:50 Thermo Scientific PP690 
IL-8 pAb dolphin 1:200 Kingfisher Biotech, Inc. PB0377P 
IL-10 mAb (IgG2b) bovine 1:50 overnight Serotec MCA2110 
IFN-γ: biotin mAb (IgG1) bovine 1:50 Serotec MCA1783B 
TGF-β mAb (IgG1) human 1:50 overnight Serotec MCA797 
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Results 
 
 
Dolphin clinical results 
The case dolphin had a clinical history of chronic, high liver enzymes 
(alanine transaminase >42 U/L, aspartate transaminase >263 U/L, and gamma-
glutamyl transpeptidase >44 U/L) and serum iron that began at the age of 25 
years and peaked at 42 years (Figure 1A; Johnson et al., 2009).  A liver biopsy at 
that time demonstrated that this dolphin had diffuse, moderate hemosiderosis, 
mild multifocal vacuolar degeneration, mild amounts of granular intracellular iron 
in hepatocytes, and moderate amounts of intracellular iron visualized via staining 
in the Kupffer cells.  The case dolphin was diagnosed with hemochromatosis 
(iron overload) and successfully treated with a 20-week course of phlebotomy 
(Johnson et al., 2009).  The dolphin was 43 years old when treatment was 
completed; all liver enzymes and serum iron values had returned to normal levels 
for this dolphin population (Venn-Watson and Ridgway, 2007). 
The case dolphin had repeatedly high 2-hour postprandial insulin levels 
(mean = 31 ± 11 µIU/mL and median = 28, range 17-52 µIU/mL, based upon 16 
sampling dates), chronically high glucose (greater than 144 mg/dL), white blood 
cell counts (greater than 12,000 cells/µL), and high and rising cholesterol (greater 
than 286 mg/dL) based upon reference values for this dolphin population (Venn-
Watson et al., 2007).  Both high insulin and cholesterol remained present after 
treatment for hemochromatosis (Figures 1B, 1C, 1D).  When the dolphin died at 
46 years old, he had no evidence of hepatic iron deposition, supporting that iron 
overload in the liver had been successfully treated.  Postmortem liver had mild, 
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subacute periportal lymphoplasmacytic inflammation; cholestasis; and mild 
diffuse, hepatocellular fatty change confirmed to be lipid type with oil red O 
staining (Venn-Watson et al., 2012).  Upon histologic evaluation, there were no 
significant findings in the pancreas or spleen. 
 
 
 
FIGURE 1 | Time series of blood value changes the case bottlenose dolphin 
(Tursiops truncatus) with treated hepatic iron overload and chronic, 
postprandial hyperinsulinemia, and mild fatty liver disease: A) alanine 
transaminase, B) glucose, C) cholesterol, and D) white blood cell count. 
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Cytokine gene expression levels in a dolphin with hyperinsulinemia as 
compared to a reference  
Tissue-specific differences in pro- and anti-inflammatory cytokine mRNA 
expression between the case and reference dolphin were observed by real-time 
PCR in the liver (Figure 2) and spleen (Figure 3).  Levels of TGF-β and TNF-α in 
the liver were upregulated, but similar to reference in the spleen.  IL-18 and IL-13 
were upregulated in both tissues.  On the other hand, IL-10 mRNA expression 
was lower than expression in the reference liver while IL-4 was upregulated; the 
opposite was true in the spleen.  IL-12p40 levels were lower in the liver and 
similar in the spleen compared to the reference dolphin.  IL-2 was not increased 
in the spleen and not detectable in the liver.  IFN-γ was lower than the the 
reference dolphin in the liver, but upregulated in the spleen. 
 
 
FIGURE 2 | Cytokine 
message levels in the 
liver of a dolphin with 
hyperinsulinemia.  In the 
liver, each target gene was 
determined by real-time 
PCR and normalized first 
to S-9, a ribosomal control 
gene to give a ΔCt.  The 
ΔΔCt was determined for 
the dolphin with 
hyperinsulinemia by 
normalizing to a healthy 
control. The ΔΔCt were transformed (2-ΔΔCt) to show the expression of each 
cytokine message as a fold change.  A fold change of 2 or more was considered 
to be upregulated in the dolphin with hyperinsulinemia. 
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FIGURE 3 | Cytokine 
message levels in the 
spleen of a dolphin with 
hyperinsulinemia. 
In the spleen, each target 
gene was determined by 
real-time PCR and 
normalized first to S-9, a 
ribosomal control gene to 
give a ΔCt.  The ΔΔCt was 
determined for the dolphin 
with hyperinsulinemia by 
normalizing to a healthy 
control. The ΔΔCt were 
transformed (2-ΔΔCt) to show the expression of each cytokine message as a fold 
change.  A fold change of 2 or more was considered to be upregulated in the 
dolphin with hyperinsulinemia. 
 
 
Cytokine expression in the spleen as detected by fluorescent IHC  
We next examined the localization of cytokines in splenic tissue samples 
from the case dolphin.  Fluorescent IHC staining using an antibody to Ki67, which 
recognizes a nuclear cell proliferation antigen, in the dolphin with 
hyperinsulinemia showed evidence of multiple germinal centers at various stages 
of development in the splenic tissue examined, with one representative example 
shown in Figure 4.  Areas of CD2 staining, the T-cell zone, surrounded the 
germinal centers.  Staining of IL-6 and IL-8 was seen in the splenic red pulp, as 
well as in the germinal centers and T-cell zones (Figure 5), while TGF-β was 
evidently localized to the red pulp of the spleen (Figure 6).  IL-1β and IL-10 
staining were seen in the T-cell zone (Figure 7).  Two different staining patterns 
were observed for IL-4; minimal staining was found within the B-cell follicle, while 
more prominent punctate staining was localized to the red pulp (Figure 7).  IFN-γ 
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staining was detected in the T-cell zone and red pulp of the spleen (Figure 8 and 
data not shown).  
 
 
FIGURE 4 | A germinal center, surrounded by a T-cell zone, in the spleen of 
a dolphin with hyperinsulinemia.  Dolphin splenic tissue sections were 
incubated with primary anti-Ki67, followed by anti-dolphin CD2, and nuclear 
staining using VECTASHIELD mounting medium with DAPI.  Original 
magnification 20x. 
 
 
 
FIGURE 5 | IL-6 and IL-8 expression in the spleen of a dolphin with 
hyperinsulinemia.  Dolphin splenic tissue sections were incubated with primary 
anti-porcine IL-6 or anti-dolphin IL-8, followed by anti-dolphin CD2, and nuclear 
staining using VECTASHIELD mounting medium with DAPI. Original  
magnification 20x. 
 
 
 
FIGURE 6 | TGF-β 
expression in the 
spleen of a dolphin 
with 
hyperinsulinemia. 
Dolphin splenic tissue sections were incubated with primary anti-human TGF-β, 
followed by nuclear staining using VECTASHIELD mounting medium with DAPI. 
Original magnification 20x. 
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FIGURE 7 | IL-1β, IL-4 and IL-10 expression in the spleen of a dolphin with 
hyperinsulinemia.  Dolphin splenic tissue sections were incubated with primary 
anti-ovine IL-β, anti-bovine IL-4, or anti-bovine IL-10, followed by anti-dolphin 
CD2, and nuclear staining using VECTASHIELD mounting medium with DAPI. 
Original magnification 20x. 
 
 
 
FIGURE 8 | IFN-γ 
expression in the 
spleen of a 
dolphin with 
hyperinsulinemia.  
Dolphin splenic 
tissue sections were incubated with primary anti-bovine IFN-γ which was biotin 
conjugated, followed by nuclear staining using VECTASHIELD mounting medium 
with DAPI. Original magnification 20x. 
 
 
 
Discussion 
 
  Compared to a reference bottlenose dolphin without metabolic 
perturbations, the current study identified activated cytokine gene expression, 
including TGF-β, TNF-α, IFN-γ, IL-18, IL-13, IL-10, and IL-4 in the liver or spleen 
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of a geriatric bottlenose dolphin with hyperinsulinemia.  The case dolphin has 
been previously identified as having insulin resistance (chronic postprandial 
hyperinsulinemia and hyperglycemia) and mild fatty liver disease (Johnson et al., 
2009; Venn-Watson et al., 2011a; Venn-Watson et al., 2012).  High white blood 
cell counts in humans can predict development of T2D, and the clinical profile of 
the case dolphin, including high white blood cell counts, supports that it had 
chronic inflammation associated with T2D (Vozarova et al., 2002).  The source of 
chronic inflammation was not evident upon histological examination. 
  This study shows that a dolphin with hyperinsulinemia and metabolic 
syndrome exhibited similar altered cytokine expression as has been shown in 
humans and mice with hyperinsulinemia and T2D.  Pro-inflammatory cytokines 
are strong contributors to increased insulin resistance, specifically TNF-α 
(Hotamisligil et al., 1995; Kern et al., 2001; Wellen and Hotamisligil, 2005; Eckel 
et al., 2005).  TNF-α interferes with the signaling of the insulin receptor 
(Hotamisligil et al., 1994b).  As expected, this dolphin with metabolic syndrome 
and hyperinsulinemia displayed levels of TNF-α in the liver that were higher than 
the reference.  IL-6 has also been linked to a hyperinsulinemic state (Eckel et al., 
2005; Kern et al., 2001).  Fluorescent IHC in the spleen of the dolphin with 
hyperinsulinemia did reveal abundant staining for IL-6.  In the hyperinsulinemic 
dolphin, IL-18 mRNA was upregulated in both the spleen and liver.  This is 
consistent with reports in humans that IL-18 predicts the development of T2D 
(Thorand et al., 2005) and that circulating levels of IL-18 are elevated in patients 
with T2D as compared to nondiabetic controls (Aso et al., 2003; Esposito et al., 
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2003; Esposito et al., 2004).  Due to the pro-inflammatory nature of 
hyperinsulinemia, it is not surprising that corresponding anti-inflammatory 
cytokines, IL-4, IL-10, IL-13, and TGF-β, would also be upregulated in an effort to 
control the inflammation.  The case dolphin, however, died unexpectedly from 
anaphylactic shock, and only one reference dolphin was used.  While this is a 
useful case study, larger scale investigations using more dolphins with and 
without hyperinsulinemia and metabolic syndrome are needed to further validate 
this study's findings.  Limitations to such large-scale studies include opportunistic 
access to properly processed fresh tissues from dolphins of known metabolic 
status. 
  Germinal center formation is a characteristic feature of T-cell dependent, 
B-cell responses and may be an important site of immune dysregulation in 
certain diseases.  Development of splenic germinal centers occurs over a period 
of days; the follicular dendritic cell network is filled with Ki76+ B cells by 7-9 days 
post-immunization in mice (Camacho et al., 1998).  As the cytokine mRNA data 
suggested the induction of cytokines known to play a role in isotype switching, 
we examined whether there was evidence of germinal center formation in areas 
adjacent to the T-cell zone or periarteriolar lymphoid sheath in the spleen.  In the 
present study, the splenic tissue of the case dolphin with hyperinsulinemia was 
found to contain numerous germinal centers containing Ki76+ cells.  Interestingly, 
this is similar to the observation of spontaneous germinal center formation that 
has been described in strains of mice that develop autoimmune type 1 diabetes 
(Luzina et al., 2001). 
 149 
  Dolphins are emerging as a model for T2D due to some similarities in 
metabolic perturbations to humans (Venn-Watson et al., 2010, 2011a, 2012).  
This study is the first to show that a dolphin with hyperinsulinemia and metabolic 
syndrome displayed a similar pro-inflammatory state as humans with 
hyperinsulinemia and T2D.  Control tissues from a number of healthy dolphins 
are needed to make any definitive conclusions based on cytokine protein levels; 
this would be necessary to determine a baseline expression of each cytokine.  It 
is also pertinent to look specifically at adipocytes and the adipokines they 
secrete, as the adipose tissue is important in regulating metabolism.  In addition 
to the cytokines included herein, IL-6 has been shown to be important in 
hyperinsulinemia in humans and alterations in levels of IL-6 the dolphin should 
be examined further.  Soluble CD163 (sCD163) was shown to be associated with 
insulin resistance in humans and may be a more reliable measure of T2D than 
TNF-α (Parkner et al., 2012); sCD163 secreted by macrophages should be 
examined further in the dolphin as well.  As used in this study, specific anti-ovine, 
-porcine, -bovine and -human cytokine antibodies were shown to cross-react with 
bottlenose dolphin tissues, as similarly described for other cetaceans (Jaber et 
al., 2010).  Reagents for use in dolphins will need to become more available for 
studying T2D and other diseases.  The availability of these reagents and dolphin-
specific reagents that we are developing in collaboration with Kingfisher Biotech, 
Inc. will facilitate studies of immune modulation in managed bottlenose dolphins. 
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